National Institute for Health and Care Excellence

Guideline version (Consultation)

Subarachnoid haemorrhage

[A] Evidence review for symptoms and signs

NICE guideline <number>

Evidence reviews underpinning

February 2021

Draft for consultation

Developed by the National Guideline Centre, hosted by the Royal College of Physicians

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn.

ISBN
[add for final publication version only, delete this text for consultation version]

Contents

1 Symptoms and signs

Evidence review underpinning recommendations 1.1.1 to 1.1.3 in the NICE guideline.

1.1 Review question: What symptoms and signs indicate subarachnoid haemorrhage?

1.2 Introduction

Acute severe headache is a common presenting symptom and places a significant burden on emergency medical services. Most people with acute headache will have a benign cause but people with suspected subarachnoid haemorrhage are potentially at risk of re-bleeding, disability and death. A missed diagnosis of SAH can therefore have severe consequences; however investigation of all people with headache, or other symptoms suggestive of subarachnoid haemorrhage, will expose some people to unnecessary risk and may not be a cost-effective strategy.

In current practice, the clinical history and physical examination are used to identify people with suspected subarachnoid haemorrhage who require further investigation. Patients with subarachnoid haemorrhage can present with a wide range of signs and symptoms and in people with a neurological deficit the decision to proceed with further investigation may be straightforward, but management decisions for people who are neurologically intact are more difficult.

This review was carried out to assess the diagnostic value of symptoms and signs of subarachnoid haemorrhage.

1.3 PICO table

For full details see the review protocol in Appendix A:.

Table 1: PICO characteristics of review question

Population	Inclusion: Adults (16 and older) with a suspected subarachnoid haemorrhage caused by a suspected ruptured aneurysm. Exclusion: • Adults with subarachnoid haemorrhage caused by head injury, ischaemic stroke or an arteriovenous malformation. • Children and young people aged 15 years and younger.
Diagnostic variable(s) under consideration	• History of headache (herald/sentinel/prodromal headache) • Sudden severe headache • Painful/stiff neck • Nausea and vomiting • Photophobia • Blurred/double vision • Loss of consciousness • Confusional state • Focal neurology (hemiparesis) • Seizure • High blood pressure (>140/90)
Reference standard/	Reference standard: • confirmed diagnosis of SAH (by CT, LP +/- angiography or post-mortem)

Confounding factors	Confounding factors: • Age

Outcome(s)	Diagnostic association of signs and symptoms with a confirmed diagnosis of aSAH.
	Measured by:
	• Diagnostic accuracy data
	  ○ Sensitivity, specificity, PPV, NPV
	• Association data
	  ○ Adjusted RR or OR

Study design	• Prospective and retrospective cohort studies with multivariate analysis will be included preferentially. • Cross-sectional studies Studies will only be included if all the key confounders have been accounted for in a multivariate analysis. In the absence of multivariate analysis, studies that account for key confounders with univariate analysis or matched groups will be considered.

1.4 Clinical evidence

1.4.1 Included studies

A search was conducted to identify studies reviewing the signs and symptoms indicating a SAH.

Five papers from 4 cohort studies were included in the review,[55, 97, 130, 132, 133] these are summarised in **Table 2** below. The trials included in this evidence review used significant signs and symptoms for a SAH to produce diagnostic decision tools. The diagnostic accuracy of these clinical decision tools and the individual signs and symptoms in diagnosing SAH were reported by these studies. The accuracy of the tools or signs and symptoms was measured against a final diagnosis of SAH, confirmed by non-contrast CT or LP (with or without supporting angiographical imaging). Where studies provided insufficient information to conduct a meta-analysis (true positives, true negatives, false positives, false negatives), or too few common studies were included (≤2 studies for the same diagnostic outcome) diagnostic accuracy results were reported individually on a per-study basis.

No evidence was identified on the diagnostic association of signs and symptoms with a confirmed diagnosis of SAH.

See also the study selection flow chart in Appendix C:, study evidence tables in Appendix D:, forest plots in Appendix E:

1.4.2 Excluded studies

See the excluded studies list in Appendix H:.

1.4.3 Summary of studies included in the evidence review

Table 2: Summary of studies

Study	Population	Analysis	Signs/symptoms	Outcomes	Comments
Kelly 2014[55]	Alert and neurologically intact adult patients with confirmed SAH N=59	Retrospective analysis of patients with diagnosis of SAH. Study design: Retrospective cohort review	**Rule 1** 1. Age ≥ 40 y 2. Neck pain or stiffness 3. Witnessed loss of consciousness 4. Onset during exertion **Rule 2** 1. Age ≥ 45 y 2. Arrival by ambulance 3. Vomiting (≥1 episodes) 4. Diastolic blood pressure ≥100mmHg **Rule 3** 1. Age 45-55 y 2. Neck pain or stiffness 3. Arrival by ambulance 4. Systolic blood pressure ≥ 160mmHg	SAH Reference standard: Diagnosis of SAH by CT head scan, CT angiography, conventional angiography, MRI or LP supported by specialist neurosurgical opinion.	Unclear how rule was applied, i.e. if all criteria had to be present or only one. Assumed patients applied if one or more of the variables were present.
Mark 2015[97]	Patients who had an ED or hospital encounter with a diagnosis code of SAH. N=155	Retrospective analysis of patients with diagnosis of SAH. Study design:	A negative result being defined as absence of all four clinical criteria. 1. Age ≥40 y	SAH Reference standard: Evidence of SAH on non-contrast cranial CT	Analysis only included patients with confirmed diagnosis of SAH. Not possible to assess rule specificity.

Study	Population	Analysis	Signs/symptoms	Outcomes	Comments
		Retrospective cohort review	2. Neck pain or stiffness 3. Witnessed loss of consciousness 4. Onset during exertion	or >5 RBC per microliter on CSF analysis, and angiographic evidence of cerebral aneurysm.	
Pathan 2018[130]	Age older than 15 years, new atraumatic headache, and headaches that reached maximal intensity in 1 hour. N=145	Retrospective review of computerized medical records of all patients registered with a headache. Study design: Retrospective cohort review	**Ottawa Rule** For alert patients older than 15y with new severe non traumatic headache reaching maximum intensity within 1 h. Investigate if ≥1 high-risk variables present: 1. Age ≥ 40 y 2. Neck pain or stiffness 3. Witnessed loss of consciousness 4. Onset during exertion 5. Thunderclap headache (instantly peaking pain) 6. Limited neck flexion on examination	SAH Reference standard: subarachnoid blood visible on a plain CT film or xanthochromia in the cerebrospinal fluid.	
Perry 2013[132]; Perry 2010[133]	Consecutive adult patients whose chief reason for visiting the emergency department was a non-traumatic headache that reached maximal intensity within 1 hour were considered for enrolment. N=2131	Potential refinement of the rules was assessed using multivariate recursive partitioning analysis. The estimated sensitivity, specificity, and C statistic for subarachnoid haemorrhage, including 95%CIs, were calculated for the refined rule.	For patients presenting with severe headache: **Rule 1** Investigate if ≥1 high-risk finding present: 1. Age ≥ 40 y 2. Neck pain or stiffness 3. Witnessed loss of consciousness	SAH Reference standard: Subarachnoid blood on unenhanced CT of the head; xanthochromia in the cerebrospinal fluid; or RBC (>1 × 106/L) in the final tube of CSF fluid, with an aneurysm or arteriovenous	Unclear of variables used for multivariate analysis to determine symptoms/signs included in clinical rules.

Study	Population	Analysis	Signs/symptoms	Outcomes	Comments
		Study design: Prospective cohort review	4. Onset during exertion **Rule 2** Investigate if ≥1 high-risk findings present: 1. Age ≥ 45 y 2. Arrival by ambulance 3. Vomiting (≥1 episodes) 4. Diastolic blood pressure ≥100mmHg **Rule 3** Investigate if ≥1 high-risk findings present: 1. Age 45-55 y 2. Neck pain or stiffness 3. Arrival by ambulance 4. Systolic blood pressure ≥ 160mmHg **Ottawa Rule** For alert patients older than 15y with new severe non traumatic headache reaching maximum intensity within 1 h. Investigate if ≥1 high-risk variables present: 1. Age ≥ 40 y 2. Neck pain or stiffness	malformation on cerebral angiography.	

Study	Population	Analysis	Signs/symptoms	Outcomes	Comments
			3. Witnessed loss of consciousness 4. Onset during exertion 5. Thunderclap headache (instantly peaking pain) 6. Limited neck flexion on examination		

1 See Appendix D: for full evidence tables.

2 1.4.4 Quality assessment of clinical studies included in the evidence review

3 **Table 3: Clinical evidence summary: Clinical decision rules for detecting SAH**

Index Test	Number of patients (studies)	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect size (95%CI)	Quality
Decision rules							
Rule 1: 1. Age ≥40 y 2. Neck pain or stiffness 3. Loss of consciousness 4. Onset during exertion	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity=98.5% (94.6 – 99.6%)	MODERATE
		Serious[a]	Not serious	Not serious	Not serious	Specificity=27.6% (25.7 – 29.6%)	MODERATE
	155 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity =95.5% (90.9-98.2%)	MODERATE
	59 (1)	Very serious[a]	Not serious	Not serious	Serious[d]	Sensitivity =96.6% (88.5-99.1%)	VERY LOW
Rule 2: 1. Age ≥ 45 y 2. Arrival by ambulance	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity= 95.5% (90.4 – 97.9%)	MODERATE
		Serious[a]	Not serious	Not serious	Not serious	Specificity= 30.6%	MODERATE

Index Test	Number of patients (studies)	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect size (95%CI)	Quality
3. Vomiting (≥1 episodes)						(28.6 – 32.6%) [e]	
4. Diastolic blood pressure ≥100mmHg	59 (1)	Very serious[a]	Not serious	Not serious	Not serious	Sensitivity =100% (93.9-100%)	LOW
Rule 3: 1. Age 45-55 y 2. Neck pain or stiffness 3. Arrival by ambulance 4. Systolic blood pressure ≥ 160mmHg	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity= 97.0% (92.5 – 98.8%)	MODERATE
		Serious[a]	Not serious	Not serious	Not serious	Specificity=35.6% (33.6 – 37.7%) [e]	MODERATE
	59 (1)	Very serious[a]	Not serious	Not serious	Serious[d]	Sensitivity =89.8% (79.5-95.3%)	VERY LOW
Ottawa rule: 1. Age ≥ 40 y 2. Neck pain or stiffness 3. Witnessed loss of consciousness 4. Onset during exertion 5. Thunderclap headache (instantly peaking pain) 6. Limited neck flexion on examination	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity=100% (97.2 – 100%)	MODERATE
		Serious[a]	Not serious	Not serious	Not serious	Specificity=15.3% (13.8 – 16.9%)	MODERATE
	145 (1)	Serious[a]	Not serious	Not serious	Very serious[d]	Sensitivity=100% (46.3 – 100%)	VERY LOW
		Serious[a]	Not serious	Not serious	Not serious	Specificity=44.2% (36 – 53%)	MODERATE

Reference standard: confirmed diagnosis of SAH by non-contrast CT or LP +/- angiography. For Kelly 2014 and Mark 2015, the timing of the reference standard relative to symptom onset was <14 days and <6 hours, respectively. The timing of reference standard diagnosis relative to symptom onset was unclear for Pathan 2018 and Perry 2010/2013.

a) Risk of bias was assessed using the QUADAS-2 checklist. The evidence was downgraded by 1 increment if the majority of studies were rated at high risk of bias, and downgraded by 2 increments if the majority of studies were rated at very high risk of bias.

b) Where possible, inconsistency was assessed by inspection of the sensitivity and specificity plots. The evidence was

- *downgraded by 1 increment if the individual study values varied across 2 areas: where values of individual studies are both above and below 50%, or both above and below 90%*
- *downgraded by 2 increments if the individual study values varied across 3 areas, where values of individual studies are above and below 50%, and also above and below 90%*

c) Indirectness was assessed using the QUADAS-2 checklist items referring to applicability. The evidence was downgraded by 1 increment if the majority of studies were seriously indirect, and downgraded by 2 increments if the majority of studies are very seriously indirect

d) Imprecision was assessed based on inspection of the confidence region in the diagnostic meta-analysis or, where diagnostic meta-analysis has not been conducted, assessed according to the range of confidence intervals in the individual studies. Two clinical decision thresholds were determined at the value above which a test would be recommended (90%), and a second below which a test would be considered of no clinical use (60%).The evidence was downgraded by 1 increment when the range of the confidence interval around the point estimate crossed one threshold, and downgraded by 2 increments when the range covered two thresholds

e) Results within the paper differ from analysis from forest plots. The results given in the table are taken from the paper directly.

1 **Table 4: Clinical evidence summary: Individual signs & symptoms for detecting SAH**

Index Test	Number of patients (studies)	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect size (95% CI)	Quality
Signs & Symptoms							
Arrived by ambulance	2131 (1)	Serious[a]	Not serious	Not serious	Serious[d]	Sensitivity = 61.4% (52-70%)	LOW
		Serious[a]	Not serious	Not serious	Not serious	Specificity = 76.1% (74-78%)	MODERATE
	59 (1)	Very serious[a]	Not serious	Not serious	Serious[d]	Sensitivity = 69.5% (56-81%)	VERY LOW
Onset during exertion	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity = 19.2% (13-27%)	MODERATE
		Serious[a]	Not serious	Not serious	Serious[d]	Specificity = 89.7% (88-91%)	LOW
	59 (1)	Very serious[a]	Not serious	Not serious	Not serious	Sensitivity = 20.3% (20-43%)	LOW
Onset during sexual activity	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity = 9.8% (5-16%)	MODERATE
		Serious[a]	Not serious	Not serious	Not serious	Specificity = 93.8% (93-95%)	MODERATE
Headache awoke patient from sleep	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity = 12.1% (7-19%)	MODERATE
		Serious[a]	Not serious	Not serious	Not serious	Specificity = 82.6% (81-84%)	MODERATE
Thunderclap headache	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity = 82.4% (75-89%)	MODERATE
		Serious[a]	Not serious	Not serious	Not serious	Specificity = 45.3% (43-48%)	MODERATE
Worst headache of life	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity = 99.2% (96-100%)	MODERATE

Index Test	Number of patients (studies)	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect size (95% CI)	Quality
		Serious[a]	Not serious	Not serious	Not serious	Specificity = 24.4% (23-26%)	MODERATE
Loss of consciousness	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity = 10.6% (6-17%)	MODERATE
		Serious[a]	Not serious	Not serious	Not serious	Specificity = 94.7% (94-96%)	MODERATE
Loss of consciousness (witnessed)	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity = 5.3% (2-11%)	MODERATE
		Serious[a]	Not serious	Not serious	Not serious	Specificity = 96.4% (95-97%)	MODERATE
	59 (1)	Very serious[a]	Not serious	Not serious	Not serious	Sensitivity = 18.6% (10-31%)	LOW
Neck pain or stiffness	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity = 76.5% (68-83%)	MODERATE
		Serious[a]	Not serious	Not serious	Not serious	Specificity = 68.4% (66-70%)	MODERATE
	59 (1)	Very serious[a]	Not serious	Not serious	Not serious	Sensitivity = 42.4% (30-56%)	LOW
Vomiting	2131 (1)	Serious[a]	Not serious	Not serious	Serious[d]	Sensitivity = 65.9% (57-74%)	LOW
		Serious[a]	Not serious	Not serious	Not serious	Specificity = 73.6% (72-76%)	MODERATE
	59 (1)	Very serious[a]	Not serious	Not serious	Serious[d]	Sensitivity = 66.1% (53-78%)	VERY LOW
Able to walk since headache	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity = 76.6% (68-83%)	MODERATE
		Serious[a]	Not serious	Not serious	Not serious	Specificity = 9.9% (9-11%)	MODERATE

Index Test	Number of patients (studies)	Risk of bias	Inconsistency	Indirectness	Imprecision	Effect size (95% CI)	Quality
Emergency department transfer	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity = 16.7% (11-24%)	MODERATE
		Serious[a]	Not serious	Not serious	Not serious	Specificity = 91.9% (91-93%)	MODERATE
Limited flexion	2131 (1)	Serious[a]	Not serious	Not serious	Not serious	Sensitivity = 28.3% (21-37%)	MODERATE
		Serious[a]	Not serious	Not serious	Not serious	Specificity = 96.8% (96-98%)	MODERATE
Diastolic blood pressure >100 mmHg	59 (1)	Very serious[a]	Not serious	Not serious	Not serious	Sensitivity = 10.2% (4-21%)	LOW
Systolic BP >160 mmHg	59 (1)	Very serious[a]	Not serious	Not serious	Not serious	Sensitivity = 30.5% (19-44%)	LOW
Age >40 years	59 (1)	Very serious[a]	Not serious	Not serious	Not serious	Sensitivity = 79.6% (67-89%)	LOW
Age >45 years	59 (1)	Very serious[a]	Not serious	Not serious	Serious[d]	Sensitivity = 69.5% (56-81%)	VERY LOW
Age 45-55 years	59 (1)	Very serious[a]	Not serious	Not serious	Not serious	Sensitivity = 27.1% (16-40%)	LOW

a) *Risk of bias was assessed using the QUADAS-2 checklist. The evidence was downgraded by 1 increment if the majority of studies were rated at high risk of bias, and downgraded by 2 increments if the majority of studies were rated at very high risk of bias.*

b) *Where possible, inconsistency was assessed by inspection of the sensitivity and specificity plots. The evidence was*
- *downgraded by 1 increment if the individual study values varied across 2 areas: where values of individual studies are both above and below 50%, or both above and below 90%*
- *downgraded by 2 increments if the individual study values varied across 3 areas, where values of individual studies are above and below 50%, and also above and below 90%*

c) *Indirectness was assessed using the QUADAS-2 checklist items referring to applicability. The evidence was downgraded by 1 increment if the majority of studies were seriously indirect, and downgraded by 2 increments if the majority of studies are very seriously indirect*

d) *Imprecision was assessed based on inspection of the confidence region in the diagnostic meta-analysis or, where diagnostic meta-analysis has not been conducted, assessed according to the range of confidence intervals in the individual studies. Two clinical decision thresholds were determined at the value above which a test would be recommended (90%), and a second below which a test would be considered of no clinical use (60%).The evidence was downgraded by 1 increment when the range of the confidence interval around the point estimate crossed one threshold, and downgraded by 2 increments when the range covered two thresholds.*

1.5 Economic evidence

1.5.1 Included studies

No health economic studies were included.

1.5.2 Excluded studies

No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.

See also the health economic study selection flow chart in Appendix F:.

1.6 Evidence statements

1.6.1 Health economic evidence statements

No relevant economic evaluations were identified.

1.7 The Committee's discussion of the evidence

1.7.1 Interpreting the evidence

1.7.1.1 The outcomes that matter most

The committee noted the primary objective of the evidence review was to assess the diagnostic accuracy and diagnostic association of signs and symptoms with a confirmed diagnosis of subarachnoid haemorrhage. Sensitivity, specificity and adjusted odds ratios or risk ratios for diagnosing subarachnoid haemorrhage were the outcomes for this review. The committee agreed that sensitivity of signs and symptoms for SAH was the most important outcome as a diagnostic indicator to correctly identify a high proportion of people with SAH and rule out the disease in those without. A highly sensitive symptom or sign would identify with accuracy those with SAH who require further neurological imaging and possible subsequent intervention. This would likely minimise the risk of neurological morbidity or subsequent rebleed that could be caused by delay to treatment. The committee agreed that a diagnostic accuracy with sensitivity of ≥90% would provide value in clinical practice. The committee also considered specificity important to correctly rule in SAH, identifying a large proportion of those without SAH with few false positive results. This would mean that few people with suspected SAH without the condition would undergo potentially unnecessary neurological imaging. The committee agreed that a specificity of ≥90% would reflect a highly accurate test.

Evidence was identified for the diagnostic accuracy of four clinical decision rules. These included:

- Rule 1: Age ≥40 y; Neck pain or stiffness; Loss of consciousness; Onset during exertion.
- Rule 2: Age ≥ 45 y; Arrival by ambulance; Vomiting (≥1 episodes); Diastolic blood pressure ≥100mmHg.
- Rule 3: Age 45-55 y; Neck pain or stiffness; Arrival by ambulance; Systolic blood pressure ≥ 160mmHg.

- Ottawa rule: Age ≥ 40 y; Neck pain or stiffness; Witnessed loss of consciousness; Onset during exertion; Thunderclap headache (instantly peaking pain); Limited neck flexion on examination.

The diagnostic accuracy of each of 18 individual signs and symptoms for SAH was also included for review.

No evidence was found for the diagnostic association (as reported by adjusted RR or OR) of signs and symptoms or clinical decision tools for a final diagnosis of SAH.

1.7.1.2 The quality of the evidence

From the studies included in this evidence review, 3 were retrospective cohort reviews and 1 was a large prospective cohort trial. The committee noted the smaller size of the retrospective cohort studies and agreed that the larger size and prospective nature of the Perry trial provided a more valuable source of information to inform discussions. Most of the evidence presented in the review was of moderate quality. This was generally due to a high risk of bias as not all patients within the studies underwent the reference standard investigation of a CT scan and/or lumbar puncture. In cases where eligible participants did not undergo CT imaging or investigation with LP, efforts were made to follow up by telephone and review of medical records to screen for possible subsequent SAH. There was also potential bias as it was unclear from the included studies why variables were specifically selected for use within the clinical decision rules. The committee noted possible selection bias as some of the include studies only included patients with confirmed SAH. Despite these limitations, the moderate quality of the evidence, particularly supported by the statistical precision demonstrated by relatively narrow confidence intervals, provided the committee with the necessary confidence to inform the recommendations. The committee used the evidence available and their experience of clinical practice to make a firm recommendation to be aware of a set of signs and symptoms which indicate SAH as a possible diagnosis and would justify immediate referral for diagnostic investigation.

1.7.1.3 Benefits and harms

Some centres have a low threshold for carrying out CT scan in people presenting to ED with headache because of concern that a missed diagnosis of SAH can have severe consequences. However, there is potential harm if every patient presenting to A&E with headache is referred for CT, as many patients would be exposed unnecessarily to ionising radiation and such a policy is unlikely to be cost-effective.

Identifying the signs and symptoms that accurately indicate a SAH would highlight the people in whom further diagnostic investigation is clinically justified. The committee noted that an accurate set of signs and symptoms correctly identifying those with the condition, would enable timely investigation and subsequent intervention to manage the bleed. The committee acknowledged the potential harms of signs and symptoms with low diagnostic value in identifying people with SAH could be severe, with missed or delayed diagnosis leading to neurological deterioration for the person with SAH.

The committee discussed the evidence from five papers reporting 4 cohort studies of signs and symptoms used in clinical assessment to indicate SAH.

One study used multivariate analysis and recursive partitioning to create clinical decision rules with high sensitivity so that a negative result would rule out subarachnoid haemorrhage. Accuracy of these decision rules with a diagnosis of SAH were reported in a further 3 studies.

No decision rules or individual signs or symptoms had levels of sensitivity and specificity of more than 90%.

All of the decision rules showed relatively high levels of sensitivity (ranging from 89.8% to 100%) and low levels of specificity (ranging from 15.3% to 44.2%). The evidence showed that Rule 1 (Age ≥40 y; Neck pain or stiffness; Loss of consciousness; Onset during exertion) had a median sensitivity of 96.6% and a specificity of 27.6%. Rule 2 (Age ≥ 45 y; Arrival by ambulance; Vomiting (≥1 episodes); Diastolic blood pressure ≥100mmHg) had a median sensitivity of 97.8% and a specificity of 30.6%. Rule 3 (Age 45-55 y; Neck pain or stiffness; Arrival by ambulance; Systolic blood pressure ≥ 160mmHg) had a median sensitivity of 93.4% and a specificity of 35.6%. The Ottawa rule (Age ≥ 40 y; Neck pain or stiffness; Witnessed loss of consciousness; Onset during exertion; Thunderclap headache; Limited neck flexion) demonstrated the highest level of sensitivity at 100%, with a median specificity of 29.8%. All tests reached a point of clinically important sensitivity, but none passed the threshold for clinically important specificity agreed by the committee.

The committee agreed that the high sensitivity of decision rules shows that as diagnostic tools, they would identify most, if not all of the people with SAH, who may need further investigation and intervention. However, the committee noted that the rules are based on symptoms and signs that are not specific to SAH (for example age ≥ 45years, arrival by ambulance, vomiting, raised diastolic BP), resulting in a low specificity. A significant number of patients were incorrectly indicated as having a SAH as the decision rules were unable to accurately rule out SAH in these people.

The committee acknowledged that the low specificity of the decision rules would lead to potentially unnecessary investigation with CT head scan or lumbar puncture in a large proportion of patients who did not have SAH, which reduces the value of the tools. The committee agreed that they could not make a recommendation to use these tools.

The diagnostic accuracy of the individual parameters used within these clinical decision rules were also reviewed by the committee, including arrival by ambulance, onset during exertion or sexual activity, thunderclap headache, loss of consciousness, neck pain or stiffness, limited neck flexion, vomiting, and high blood pressure. The evidence showed that thunderclap headache, neck pain or stiffness, and vomiting had highest diagnostic accuracy of individual signs and symptoms with regards to combined sensitivity and specificity. Taking the evidence from the largest and prospective study, thunderclap headache had a sensitivity of 82.4% and specificity of 45.3%, neck pain or stiffness a sensitivity of 76.5% and specificity of 68.4%, and vomiting a sensitivity of 65.9% and specificity of 73.6%. While these did not meet the threshold of 90% sensitivity and specificity the committee considered these were useful in distinguishing people who might benefit from further investigation. The committee also noted that, from their clinical experience, signs and symptoms of photophobia and altered neurology (such as reduced consciousness, a seizure or a focal neurological deficit) also raise the clinical suspicion of SAH and considered these important to consider during a clinical assessment.

The committee agreed that on balance based on their clinical experience and supported by the evidence presented, thunderclap headache is present in most people who have SAH and therefore included this as a particularly important part of the medical history. They included the other symptoms and signs in the recommendation based on their clinical experience and on the evidence presented (for neck pain or stiffness, and vomiting) as important parts of the history when considering SAH and guiding decisions on further diagnostic investigations.

1.7.2 Cost effectiveness and resource use

No published economic evaluations were identified for this review.

The committee noted that in current practice the symptoms and signs used to select people for investigation for subarachnoid haemorrhage vary substantially. Due to the concerns about a missed diagnosis, however, investigations such as a CT head scan are frequently performed to help rule out subarachnoid haemorrhage.

The committee considered that the recommendations are unlikely to have a substantial impact on current practice and will therefore not have a substantial resource impact.

1.7.3 Other factors the committee took into account

The committee recognised that the Ottawa rule is a validated clinical decision tool and has shown capacity to accurately rule out SAH with a high level of sensitivity. However, the committee highlighted the low specificity of the Ottawa rule and other clinical decision rules, and that only components of the score, rather than the overall rules are used widely in clinical practice. These factors supported the committee's decision to recommend a set of symptoms and signs as clinical indicators of SAH. The committee agreed that the recommendations made reflect current practice.

The difficulty of diagnosis in people with learning disabilities or with impaired consciousness was discussed by the committee. In such circumstances the health professional should seek information on symptoms and signs observed by the patient's relatives, carers or witnesses where possible. A recommendation was made to reflect this point.

References

1. Acuña MY, Cifuentes LA. Aneurismal subarachnoid hemorrhage in a Chilean population, with emphasis on risk factors. BMC Research Notes. 2011; 4:464

2. Alimohamadi M, Saghafinia M, Alikhani F, Danial Z, Shirani M, Amirjamshidi A. Impact of electrolyte imbalances on the outcome of aneurysmal subarachnoid hemorrhage: A prospective study. Asian Journal of Neurosurgery. 2016; 11(1):29-33

3. Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003; 34(8):2060-2065

4. Arima H, Anderson C, Omae T, Woodward M, MacMahon S, Mancia G et al. Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy: the PROGRESS trial. Stroke. 2012; 43(6):1675-1677

5. Arima H, Anderson C, Omar T, Woodward M, MacMahon S, Mancia G. Effects of blood pressure lowering on intracranial and extracranial bleeding among patients with antithrombotic therapy: the PROGRESS trial. Cerebrovascular Diseases. 2012; 33(Suppl. 2):48-49

6. Asari S, Ohmoto T. Natural history and risk factors of unruptured cerebral aneurysms. Clinical Neurology and Neurosurgery. 1993; 95(3):205-214

7. Backes D, Rinkel GJ, Laban KG, Algra A, Vergouwen MD. Patient- and aneurysm-specific risk factors for intracranial aneurysm growth: a systematic review and meta-analysis. Stroke. 2016; 47(4):951-957

8. Backes D, Vergouwen MD, Tiel Groenestege AT, Bor AS, Velthuis BK, Greving JP et al. PHASES score for prediction of intracranial aneurysm growth. Stroke. 2015; 46(5):1221-1226

9. Bassi P, Bandera R, Loiero M, Tognoni G, Mangoni A. Warning signs in subarachnoid hemorrhage: a cooperative study. Acta Neurologica Scandinavica. 1991; 84(4):277-281

10. Bhat AR, Afzalwani M, Kirmani AR. Subarachnoid hemorrhage in Kashmir: causes, risk factors, and outcome. Asian Journal of Neurosurgery. 2011; 6(2):57-71

11. Bijlenga P, Gondar R, Schilling S, Morel S, Hirsch S, Cuony J et al. PHASES score for the management of intracranial aneurysm: a cross-sectional population-based retrospective study. Stroke. 2017; 48(8):2105-2112

12. Bolouki A, Izadi S, Shahraki HR, Owji SH, Babaei AH. Clinical manifestation and factors associated with hospital mortality rate among patients with subarachnoid hemorrhage. Pakistan Journal of Medical and Health Sciences. 2019; 13(1):198-201

13. Bonilha L, Marques EL, Carelli EF, Fernandes YB, Cardoso AC, Maldaum MV et al. Risk factors and outcome in 100 patients with aneurysmal subarachnoid hemorrhage. Arquivos de Neuro-Psiquiatria. 2001; 59(3-B):676-680

14. Breen DP, Duncan CW, Pope AE, Gray AJ, Al-Shahi Salman R. Emergency department evaluation of sudden, severe headache. QJM. 2008; 101(6):435-443

15. Canhao P, Falcao F, Pinho e Melo T, Ferro H, Ferro J. Vascular risk factors for perimesencephalic nonaneurysmal subarachnoid hemorrhage. Journal of Neurology. 1999; 246(6):492-496

16. Chertcoff A, Bandeo L, Pantiu F, Cejas LL, Pacha S, Roca CU et al. Convexity subarachnoid hemorrhage: clinical features and etiology of an Argentinian cohort. Arquivos de Neuro-Psiquiatria. 2017; 75(12):858-861

17. Cho JY, Lee WS, Park YS, Lee SH, Koh JS. Clinical characteristics and prognostic factors in hemophiliacs with intracranial hemorrhage: A single-center, retrospective experience. Indian Journal of Hematology & Blood Transfusion. 2016; 32(4):488-493

18. Donnan GA, You RX, Thrift A, McNeil JJ, Johnston CI. Hypertension as a risk factor for stroke subtypes. Hypertension Research - Clinical and Experimental. 1994; 17(Suppl. 1):S51-S54

19. Duan W, Pan Y, Wang C, Wang Y, Zhao X, Wang Y et al. Risk factors and clinical impact of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: Analysis from the China National Stroke Registry. Neuroepidemiology. 2018; 50(3-4):128-136

20. Ellamushi HE, Grieve JP, Jager HR, Kitchen ND. Risk factors for the formation of multiple intracranial aneurysms. Journal of Neurosurgery. 2001; 94(5):728-732

21. Feigin V, Parag V, Lawes CM, Rodgers A, Suh I, Woodward M et al. Smoking and elevated blood pressure are the most important risk factors for subarachnoid hemorrhage in the Asia-Pacific region: an overview of 26 cohorts involving 306,620 participants. Stroke. 2005; 36(7):1360-1365

22. Fogelholm R, Murros K. Cigarette smoking and risk of primary intracerebral haemorrhage. A population-based case-control study. Acta Neurologica Scandinavica. 1993; 87(5):367-370

23. Fogelholm R, Murros K. Cigarette smoking and subarachnoid haemorrhage: a population-based case-control study. Journal of Neurology Neurosurgery and Psychiatry. 1987; 50(1):78-80

24. Foreman PM, Hendrix P, Harrigan MR, Fisher WS, 3rd, Vyas NA, Lipsky RH et al. PHASES score applied to a prospective cohort of aneurysmal subarachnoid hemorrhage patients. Journal of Clinical Neuroscience. 2018; 53:69-73

25. Fridriksson S, Hillman J, Landtblom AM, Boive J. Education of referring doctors about sudden onset headache in subarachnoid hemorrhage. A prospective study. Acta Neurologica Scandinavica. 2001; 103(4):238-242

26. Garbe E, Kreisel SH, Behr S. Risk of subarachnoid hemorrhage and early case fatality associated with outpatient antithrombotic drug use. Stroke. 2013; 44(9):2422-2426

27. Giordan E, Sorenson TJ, Brinjikji W, Vine R, Lanzino G. Risk factors for growth of conservatively managed unruptured intracranial aneurysms. Acta Neurochirurgica. 2018; 160(12):2419-2423

28. Giroud M, Creisson E, Fayolle H, Andre N, Becker F, Martin D et al. Risk factors for primary cerebral hemorrhage: a population-based study--the Stroke Registry of Dijon. Neuroepidemiology. 1995; 14(1):20-26

29. Greving JP, Wermer MJ, Brown RD, Jr., Morita A, Juvela S, Yonekura M et al. Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms: a pooled analysis of six prospective cohort studies. Lancet Neurology. 2014; 13(1):59-66

30. Gu YX, Chen XC, Song DL, Leng B, Zhao F. Risk factors for intracranial aneurysm in a Chinese ethnic population. Chinese Medical Journal. 2006; 119(16):1359-1364

31. Guo LM, Zhou HY, Xu JW, Wang Y, Qiu YM, Jiang JY. Risk factors related to aneurysmal rebleeding. World Neurosurgery. 2011; 76(3-4):292-298; discussion 253-294

32. Ha SK, Lim DJ, Kang SH, Kim SH, Park JY, Chung YG. Analysis of multiple factors affecting surgical outcomes of proximal middle cerebral artery aneurysms. Clinical Neurology and Neurosurgery. 2011; 113(5):362-367

33. Haffaf I, Clarencon F, Shotar E, Rolla-Bigliani C, Vande Perre S, Mathon B et al. Medina embolization device for the treatment of intracranial aneurysms: 18 months' angiographic results. Journal of Neurointerventional Surgery. 2019; 11(5):516-522

34. Hamann GF, Strittmatter M, Hoffmann KH, Holzer G, Stoll M, Keshevar T et al. Pattern of elevation of urine catecholamines in intracerebral haemorrhage. Acta Neurochirurgica. 1995; 132(1-3):42-47

35. Hamdan A, Barnes J, Mitchell P. Subarachnoid hemorrhage and the female sex: analysis of risk factors, aneurysm characteristics, and outcomes. Journal of Neurosurgery. 2014; 121(6):1367-1373

36. Han MH, Ryu JI, Kim CH, Kim JM, Cheong JH, Yi HJ. Predictive factors for recurrence and clinical outcomes in patients with chronic subdural hematoma. Journal of Neurosurgery. 2017; 127(5):1117-1125

37. Hanefeld C, Haschemi A, Lampert T, Trampisch HJ, Mugge A, Miebach J et al. Social gradients in myocardial infarction and stroke diagnoses in emergency medicine. Deutsches Arzteblatt International. 2018; 115(4):41-48

38. Harmsen P, Rosengren A, Tsipogianni A, Wilhelmsen L. Risk factors for stroke in middle-aged men in Goteborg, Sweden. Stroke. 1990; 21(2):223-229

39. Hatcher S, Chen C, Govindarajan P. Prehospital systolic hypertension and outcomes in patients with spontaneous intracerebral hemorrhage. Cureus. 2017; 9(1):e998

40. Hauerberg J, Andersen BB, Eskesen V, Rosenorn J, Schmidt K. Importance of the recognition of a warning leak as a sign of a ruptured intracranial aneurysm. Acta Neurologica Scandinavica. 1991; 83(1):61-64

41. Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CD et al. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke. 2003; 34(6):1457-1463

42. Honig A, Michael S, Eliahou R, Leker RR. Central fever in patients with spontaneous intracerebral hemorrhage: predicting factors and impact on outcome. BMC Neurology. 2015; 15:6

43. Hylleraas S, Davidsen EM, Benth JS, Gulbrandsen P, Dietrichs E. The usefulness of testing head and neck muscle tenderness and neck mobility in acute headache patients. Functional Neurology. 2010; 25(1):27-31

44. Inamasu J, Oheda M, Hayashi T, Kato Y, Hirose Y. Are admission systolic blood pressures predictive of outcomes in patients with spontaneous intracerebral haemorrhage after aggressive blood pressure management? European Journal of Emergency Medicine. 2015; 22(3):170-175

45. Inamasu J, Oheda M, Ito K, Kato Y, Hirose Y. Relationship between systolic blood pressures measured in emergency department and outcomes in patients with subarachnoid hemorrhage. Acute Medicine & Surgery. 2015; 2(1):35-39

46. Ivan ME, Safaee MM, Martirosyan NL, Rodriguez-Hernandez A, Sullinger B, Kuruppu P et al. Anatomical triangles defining routes to anterior communicating artery aneurysms: the junctional and precommunicating triangles and the role of dome projection. Journal of Neurosurgery. 2019; 132(5):1517-1528

47. Jabbarli R, Dinger TF, Darkwah Oppong M, Pierscianek D, Dammann P, Wrede KH et al. Risk factors for and clinical consequences of multiple intracranial aneurysms: a systematic review and meta-analysis. Stroke. 2018; 49(4):848-855

48. Jabbarli R, Rauschenbach L, Dinger TF, Darkwah Oppong M, Rodemerk J, Pierscianek D et al. In the wall lies the truth: a systematic review of diagnostic markers in intracranial aneurysms. Brain Pathology. 2020; 30(3):437-445

49. Jakobsson KE, Saveland H, Hillman J, Edner G, Zygmunt S, Brandt L et al. Warning leak and management outcome in aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery. 1996; 85(6):995-999

50. Jerntorp P, Berglund G. Stroke registry in Malmo, Sweden. Stroke. 1992; 23(3):357-361

51. Jiang H, Weng YX, Zhu Y, Shen J, Pan JW, Zhan RY. Patient and aneurysm characteristics associated with rupture risk of multiple intracranial aneurysms in the anterior circulation system. Acta Neurochirurgica. 2016; 158(7):1367-1375

52. Juvela S, Hillbom M, Palomaki H. Risk factors for spontaneous intracerebral hemorrhage. Stroke. 1995; 26(9):1558-1564

53. Kann BR, Matsumoto T, Kerstein MD. Safety of carotid endarterectomy associated with small intracranial aneurysms. Southern Medical Journal. 1997; 90(12):1213-1216

54. Katz JN, Gore JM, Amin A, Anderson FA, Dasta JF, Ferguson JJ et al. Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension (STAT) registry. American Heart Journal. 2009; 158(4):599-606.e591

55. Kelly AM, Klim S, Edward S, Millar N. Sensitivity of proposed clinical decision rules for subarachnoid haemorrhage: an external validation study. Emergency Medicine Australasia. 2014; 26(6):556-560

56. Khan M, Sivilotti ML, Bullard MJ, Emond M, Sutherland J, Worster A et al. Factors influencing time to computed tomography in emergency department patients with suspected subarachnoid haemorrhage. Emergency Medicine Journal. 2017; 34(1):20-26

57. Kim B, Jeong H, Kim J, Kim T, Kim K, Lee H et al. Incidence and risk factors of delayed intracranial hemorrhage in the emergency department. American Journal of Emergency Medicine. 2018; 36(2):271-276

58. Kim JS, Choi-Kwon S. Risk factors for stroke in different levels of cerebral arterial disease. European Neurology. 1999; 42(3):150-156

59. Kinnecom C, Lev MH, Wendell L, Smith EE, Rosand J, Frosch MP et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology. 2007; 68(17):1411-1416

60. Kleinpeter G, Lehr S. Characterization of risk factor differences in perimesencephalic subarachnoid hemorrhage. Minimally Invasive Neurosurgery. 2003; 46(3):142-148

61. Koivunen RJ, Satopaa J, Meretoja A, Strbian D, Haapaniemi E, Niemela M et al. Incidence, risk factors, etiology, severity and short-term outcome of non-traumatic

intracerebral hemorrhage in young adults. European Journal of Neurology. 2015; 22(1):123-132

62. Konczalla J, Platz J, Schuss P, Vatter H, Seifert V, Guresir E. Non-aneurysmal non-traumatic subarachnoid hemorrhage: patient characteristics, clinical outcome and prognostic factors based on a single-center experience in 125 patients. BMC Neurology. 2014; 14:140

63. Koopman I, Greving JP, van der Schaaf IC, van der Zwan A, Rinkel GJE, Vergouwen MDI. Aneurysm characteristics and risk of rebleeding after subarachnoid haemorrhage. European Stroke Journal. 2019; 4(2):153-159

64. Korja M, Silventoinen K, Laatikainen T, Jousilahti P, Salomaa V, Hernesniemi J et al. Risk factors and their combined effects on the incidence rate of subarachnoid hemorrhage--a population-based cohort study. PloS One. 2013; 8(9):e73760

65. Koshy L, Easwer HV, Premkumar S, Alapatt JP, Pillai AM, Nair S et al. Risk factors for aneurysmal subarachnoid hemorrhage in an Indian population. Cerebrovascular Diseases. 2010; 29(3):268-274

66. Kumral E, Evyapan D, Balkir K. Acute caudate vascular lesions. Stroke. 1999; 30(1):100-108

67. Lacey B, Lewington S, Clarke R, Kong XL, Chen Y, Guo Y et al. Age-specific association between blood pressure and vascular and non-vascular chronic diseases in 0.5 million adults in China: a prospective cohort study. Lancet Global Health. 2018; 6(6):e641-e649

68. Lai LT, Morgan MK, Patel NJ. Smoking increases the risk of de novo intracranial aneurysms. World Neurosurgery. 2014; 82(1-2):e195-201

69. Lansley J, Selai C, Krishnan AS, Lobotesis K, Jager HR. Subarachnoid haemorrhage guidelines and clinical practice: a cross-sectional study of emergency department consultants' and neurospecialists' views and risk tolerances. BMJ Open. 2016; 6(9):e012357

70. Le Roux PD, Elliott JP, Eskridge JM, Cohen W, Winn HR. Risks and benefits of diagnostic angiography after aneurysm surgery: a retrospective analysis of 597 studies. Neurosurgery. 1998; 42(6):1248-1254; discussion 1254-1245

71. Le Roux PD, Elliott JP, Newell DW, Grady MS, Winn HR. Predicting outcome in poor-grade patients with subarachnoid hemorrhage: a retrospective review of 159 aggressively managed cases. Journal of Neurosurgery. 1996; 85(1):39-49

72. Leira R, Castellanos M, Alvarez-Sabin J, Diez-Tejedor E, Davalos A, Castillo J et al. Headache in cerebral hemorrhage is associated with inflammatory markers and higher residual cavity. Headache. 2005; 45(9):1236-1243

73. Lepojarvi M, Peltola T, Ylonen K, Juvonen T, Pokela R, Karkola P. Cerebral haemorrhage after carotid endarterectomy. Annales Chirurgiae et Gynaecologiae. 1996; 85(1):23-26

74. Leppala JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke. 1999; 30(12):2535-2540

75. Lewis SB, Chang DJ, Peace DA, Lafrentz PJ, Day AL. Distal posterior inferior cerebellar artery aneurysms: clinical features and management. Journal of Neurosurgery. 2002; 97(4):756-766

76. Li Q, Yang WS, Chen SL, Lv FR, Lv FJ, Hu X et al. Black hole sign predicts poor outcome in patients with intracerebral hemorrhage. Cerebrovascular Diseases. 2018; 45(1-2):48-53

77. Li Q, Yang WS, Wang XC, Cao D, Zhu D, Lv FJ et al. Blend sign predicts poor outcome in patients with intracerebral hemorrhage. PloS One. 2017; 12(8):e0183082

78. Li Q, Zhang G, Huang YJ, Dong MX, Lv FJ, Wei X et al. Blend sign on computed tomography: novel and reliable predictor for early hematoma growth in patients with intracerebral hemorrhage. Stroke. 2015; 46(8):2119-2123

79. Li W, Jin C, Vaidya A, Wu Y, Rexrode K, Zheng X et al. Blood pressure trajectories and the risk of intracerebral hemorrhage and cerebral infarction: A prospective study. Hypertension. 2017; 70(3):508-514

80. Liang JW, Cifrese L, Ostojic LV, Shah SO, Dhamoon MS. Preventable readmissions and predictors of readmission after subarachnoid hemorrhage. Neurocritical Care. 2018; 29(3):336-343

81. Lindbohm JV, Kaprio J, Jousilahti P, Salomaa V, Korja M. Risk factors of sudden death from subarachnoid hemorrhage. Stroke. 2017; 48(9):2399-2404

82. Lindbohm JV, Kaprio J, Jousilahti P, Salomaa V, Korja M. Sex, smoking, and risk for subarachnoid hemorrhage. Stroke. 2016; 47(8):1975-1981

83. Lindbohm JV, Kaprio J, Korja M. Cholesterol as a risk factor for subarachnoid hemorrhage: a systematic review. PloS One. 2016; 11(4):e0152568

84. Lindekleiv H, Sandvei MS, Njolstad I, Lochen ML, Romundstad PR, Vatten L et al. Sex differences in risk factors for aneurysmal subarachnoid hemorrhage: a cohort study. Neurology. 2011; 76(7):637-643

85. Linn FH, Rinkel GJ, Algra A, van Gijn J. Headache characteristics in subarachnoid haemorrhage and benign thunderclap headache. Journal of Neurology, Neurosurgery and Psychiatry. 1998; 65(5):791-793

86. Linn FH, Wijdicks EF, van der Graaf Y, Weerdesteyn-van Vliet FA, Bartelds AI, van Gijn J. Prospective study of sentinel headache in aneurysmal subarachnoid haemorrhage. Lancet. 1994; 344(8922):590-593

87. Liotta EM, Singh M, Kosteva AR, Beaumont JL, Guth JC, Bauer RM et al. Predictors of 30-day readmission after intracerebral hemorrhage: a single-center approach for identifying potentially modifiable associations with readmission. Critical Care Medicine. 2013; 41(12):2762-2769

88. Little AS, Kerrigan JF, McDougall CG, Zabramski JM, Albuquerque FC, Nakaji P et al. Nonconvulsive status epilepticus in patients suffering spontaneous subarachnoid hemorrhage. Journal of Neurosurgery. 2007; 106(5):805-811

89. Liu J, Song J, Zhao D, Li H, Lu Y, Wu G et al. Risk factors responsible for the volume of hemorrhage in aneurysmal subarachnoid hemorrhage. Neurology India. 2016; 64(4):686-691

90. Ljubisavljevic S, Milosevic V, Stojanov A, Ljubisavljevic M, Dunjic O, Zivkovic M. Identification of clinical and paraclinical findings predictive for headache occurrence during spontaneous subarachnoid hemorrhage. Clinical Neurology and Neurosurgery. 2017; 158:40-45

91. Lo BW, Fukuda H, Nishimura Y, Macdonald RL, Farrokhyar F, Thabane L et al. Pathophysiologic mechanisms of brain-body associations in ruptured brain aneurysms: A systematic review. Surgical Neurology International. 2015; 6:136

92. Loumiotis I, Wagenbach A, Brown RD, Jr., Lanzino G. Small (< 10-mm) incidentally found intracranial aneurysms, Part 1: reasons for detection, demographics, location, and risk factors in 212 consecutive patients. Neurosurgical Focus. 2011; 31(6):E3

93. Lund Haheim L, Holme I, Hjermann I, Tonstad S. Risk-factor profile for the incidence of subarachnoid and intracerebral haemorrhage, cerebral infarction, and unspecified stroke during 21 years' follow-up in men. Scandinavian Journal of Public Health. 2006; 34(6):589-597

94. Ma C, Gurol ME, Huang Z, Lichtenstein A, Wang X, Wang Y et al. Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage: a prospective study, systematic review, and meta-analysis (P18-029-19). Current Developments in Nutrition. 2019; 3(Suppl 1):1573

95. Ma C, Gurol ME, Huang Z, Lichtenstein AH, Wang X, Wang Y et al. Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage: a prospective study. Neurology. 2019; 93(5):e445-e457

96. Ma X, Yang Y, Zhou Y, Jia W. Endovascular treatment of ruptured intracranial aneurysms in elderly patients: clinical features and treatment outcome. Neurosurgical Review. 2019; 42(3):745-751

97. Mark DG, Kene MV, Udaltsova N, Vinson DR, Ballard DW. Sensitivity of a clinical decision rule and early computed tomography in aneurysmal subarachnoid hemorrhage. Western Journal of Emergency Medicine. 2015; 16(5):671-676

98. Mark DG, Kene MV, Vinson DR, Ballard DW. Outcomes following possible undiagnosed aneurysmal subarachnoid hemorrhage: a contemporary analysis. Academic Emergency Medicine. 2017; 24(12):1451-1463

99. Menon GR, Nair S, Rao RM, Abraham M, Easwer HV, Krishnakumar K. Patterns and predictors of in-hospital aneurysmal rebleed: an institutional experience and review of literature. Annals of Indian Academy of Neurology. 2007; 10(4):247-251

100. Mensing LA, Ruigrok YM, Greebe P, Vlak MH, Algra A, Rinkel GJ. Risk factors in patients with perimesencephalic hemorrhage. European Journal of Neurology. 2014; 21(6):816-819

101. Mensing LA, Vergouwen MDI, Laban KG, Ruigrok YM, Velthuis BK, Algra A et al. Perimesencephalic hemorrhage: a review of epidemiology, risk factors, presumed cause, clinical course, and outcome. Stroke. 2018; 49(6):1363-1370

102. Meretoja A, Strbian D, Putaala J, Curtze S, Haapaniemi E, Mustanoja S et al. SMASH-U: a proposal for etiologic classification of intracerebral hemorrhage. Stroke. 2012; 43(10):2592-2597

103. Migdal VL, Wu WK, Long D, McNaughton CD, Ward MJ, Self WH. Risk-benefit analysis of lumbar puncture to evaluate for nontraumatic subarachnoid hemorrhage in adult ED patients. American Journal of Emergency Medicine. 2015; 33(11):1597-1601

104. Misbach J. Pattern of hospitalized-stroke patients in ASEAN countries an ASNA stroke epidemiological study. Medical Journal of Indonesia. 2001; 10(1):48-56

105. Mitsos AP, Corkill RA, Lalloo S, Kuker W, Byrne JV. Idiopathic aneurysms of distal cerebellar arteries: endovascular treatment after rupture. Neuroradiology. 2008; 50(2):161-170

106. Miyagi T, Koga M, Yamagami H, Okuda S, Okada Y, Kimura K et al. Reduced estimated glomerular filtration rate affects outcomes 3 months after intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. Journal of Stroke and Cerebrovascular Diseases. 2015; 24(1):176-182

107. Moon J, Cho YD, Yoo DH, Lee J, Kang HS, Cho WS et al. Growth of asymptomatic intracranial fusiform aneurysms : incidence and risk factors. Clinical Neuroradiology. 2019; 29(4):717-723

108. Morgenstern LB, Huber JC, Luna-Gonzales H, Saldin KR, Grotta JC, Shaw SG et al. Headache in the emergency department. Headache. 2001; 41(6):537-541

109. Munoz-Rivas N, Mendez-Bailon M, Hernandez-Barrera V, de Miguel-Yanes JM, Jimenez-Garcia R, Esteban-Hernandez J et al. Type 2 diabetes and hemorrhagic stroke: a population-based study in spain from 2003 to 2012. Journal of Stroke and Cerebrovascular Diseases. 2016; 25(6):1431-1443

110. Nabaweesi-Batuka J, Kitunguu PK, Kiboi JG. Pattern of cerebral aneurysms in a Kenyan population as seen at an urban hospital. World Neurosurgery. 2016; 87:255-265

111. Nahed BV, DiLuna ML, Morgan T, Ocal E, Hawkins AA, Ozduman K et al. Hypertension, age, and location predict rupture of small intracranial aneurysms. Neurosurgery. 2005; 57(4):676-683; discussion 676-683

112. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [updated October 2018]. London. National Institute for Health and Care Excellence, 2014. Available from: http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview

113. Naval NS, Mirski MA, Carhuapoma JR. Impact of statins on validation of ICH mortality prediction models. Neurological Research. 2009; 31(4):425-429

114. Neil-Dwyer G, Lang D, Smith P, Iannotti F. Outcome after aneurysmal subarachnoid haemorrhage: the use of a graphical model in the assessment of risk factors. Acta Neurochirurgica. 1998; 140(10):1019-1027

115. Nemer JA, Tallick SA, O'Connor RE, Reese CL. Emergency medical services transport of patients with headache: mode of arrival may indicate serious etiology. Prehospital Emergency Care. 1998; 2(4):304-307

116. Newman WC, Kubilis PS, Hoh BL. Validation of a neurovascular comorbidities index for retrospective database analysis. Journal of Neurosurgery. 2018; 130(1):273-277

117. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurology. 2009; 8(7):635-642

118. Nogueira GJ. Spontaneous subarachnoid haemorrhage and ruptured aneurysms in the Middle East. A myth revisited. Acta Neurochirurgica. 1992; 114(1-2):20-25

119. Nogueira J, Abreu P, Guilherme P, Felix AC, Ferreira F, Nzwalo H et al. Frequent emergency department visits after spontaneous intracerebral hemorrhage: who is at risk? The Neurohospitalist. 2018; 8(4):166-170

120. Oder W, Kollegger H, Zeiler K, Dal-Bianco P, Wessely P, Deecke L. Subarachnoid hemorrhage of unknown etiology: early prognostic factors for long-term functional capacity. Journal of Neurosurgery. 1991; 74(4):601-605

121. Ogun SA, Oluwole O, Fatade B, Ogunseyinde AO, Ojini FI, Odusote KA. Comparison of Siriraj Stroke Score and the WHO criteria in the clinical classification of stroke subtypes. African Journal of Medicine and Medical Sciences. 2002; 31(1):13-16

122. Ogun SA, Oluwole S, Aogunseyinde O, A OF, Ojini F, K AO. Accuracy of the Siriraj stroke score in differentiating cerebral haemorraghe and infarction in African Nigerians. African Journal of Neurological Sciences. 2001; 20(1)

123. Ogunlaja OI, Cowan R. Subarachnoid hemorrhage and headache. Current Pain & Headache Reports. 2019; 23(6):44

124. Ohkuma H, Tabata H, Suzuki S, Islam MS. Risk factors for aneurysmal subarachnoid hemorrhage in Aomori, Japan. Stroke. 2003; 34(1):96-100

125. Ohtani R, Kazui S, Tomimoto H, Minematsu K, Naritomi H. Clinical and radiographic features of lobar cerebral hemorrhage: hypertensive versus non-hypertensive cases. Internal Medicine. 2003; 42(7):576-580

126. Ois A, Vivas E, Figueras-Aguirre G, Guimaraens L, Cuadrado-Godia E, Avellaneda C et al. Misdiagnosis worsens prognosis in subarachnoid hemorrhage with good Hunt and Hess score. Stroke. 2019; 50(11):3072-3076

127. Olavarria VV, Bustamante G, Lopez MJ, Lavados PM. Diagnostic accuracy of a simple clinical score to screen for vascular abnormalities in patients with intracerebral hemorrhage. Journal of Stroke and Cerebrovascular Diseases. 2014; 23(8):2069-2074

128. Oppong MD, Gumus M, Pierscianek D, Herten A, Kneist A, Wrede K et al. Aneurysm rebleeding before therapy: a predictable disaster? Journal of Neurosurgery. 2019; 131(5):1473-1480

129. Ozeren A, Bicakci S, Burgut R, Sarica Y, Bozdemir H. Accuracy of bedside diagnosis versus Allen and Siriraj stroke scores in Turkish patients. European Journal of Neurology. 2006; 13(6):611-615

130. Pathan AS, Chakarova E, Tarique A. To head CT scan or not: the clinical quandary in suspected subarachnoid hemorrhage; a validation study on Ottawa Subarachnoid Hemorrhage Rule. Advanced Journal of Emergency Medicine. 2018; 2(3):e28

131. Pavlovic T, Milosevic M, Trtica S, Jelavic-Kojic F, Budincevic H, Crvenkovic D. Computed tomography in emergency department in patients with headache witout focal neurological abnormalities. Romanian Journal of Neurology. 2018; 17(1):16-19

132. Perry JJ, Stiell IG, Sivilotti ML, Bullard MJ, Hohl CM, Sutherland J et al. Clinical decision rules to rule out subarachnoid hemorrhage for acute headache. JAMA. 2013; 310(12):1248-1255

133. Perry JJ, Stiell IG, Sivilotti ML, Bullard MJ, Lee JS, Eisenhauer M et al. High risk clinical characteristics for subarachnoid haemorrhage in patients with acute headache: prospective cohort study. BMJ. 2010; 341:c5204

134. Perry JJ, Stiell IG, Wells GA, Mortensen M, Lesiuk H, Sivilotti M et al. Attitudes and judgment of emergency physicians in the management of patients with acute headache. Academic Emergency Medicine. 2005; 12(1):33-37

135. Pierot L, Barbe C, Ferre JC, Cognard C, Soize S, White P et al. Patient and aneurysm factors associated with aneurysm rupture in the population of the ARETA study. Journal of Neuroradiology. 2020; 47(4):292-300

136. Pinto AN, Canhao P, Ferro JM. Seizures at the onset of subarachnoid haemorrhage. Journal of Neurology. 1996; 243(2):161-164

137. Plata Bello J, Acosta-Lopez S, Garcia-Marin V. Clinical features and complications in idiopathic subarachnoid hemorrhage: case studies. Journal of Neurological Surgery. 2016; 77(3):222-228

138. Polmear A. Sentinel headaches in aneurysmal subarachnoid haemorrhage: what is the true incidence? A systematic review. Cephalalgia. 2003; 23(10):935-941

139. Powell J, Sanderson M, Lang E. CT HEAD? Reviewing the newest validation of the Ottawa Subarachnoid Hemorrhage Rule. Canadian Journal of Emergency Medicine. 2018; 20(6):941-943

140. Qian Z, Kang H, Tang K, Jiang C, Wu Z, Li Y et al. Assessment of risk of aneurysmal rupture in patients with normotensives, controlled hypertension, and uncontrolled hypertension. Journal of Stroke and Cerebrovascular Diseases. 2016; 25(7):1746-1752

141. Refai D, Botros JA, Strom RG, Derdeyn CP, Sharma A, Zipfel GJ. Spontaneous isolated convexity subarachnoid hemorrhage: presentation, radiological findings, differential diagnosis, and clinical course. Journal of Neurosurgery. 2008; 109(6):1034-1041

142. Rico M, Benavente L, Para M, Santamarta E, Pascual J, Calleja S. Headache as a crucial symptom in the etiology of convexal subarachnoid hemorrhage. Headache. 2014; 54(3):545-550

143. Rodriguez-Luna D, Rodriguez-Villatoro N, Juega JM, Boned S, Muchada M, Sanjuan E et al. Prehospital systolic blood pressure is related to intracerebral hemorrhage volume on admission. Stroke. 2018; 49(1):204-206

144. Rosenorn J, Eskesen V. Patients with ruptured intracranial saccular aneurysms: clinical features and outcome according to the size. British Journal of Neurosurgery. 1994; 8(1):73-78

145. Rush B, Wiskar K, Fruhstorfer C, Hertz P. Association between seizures and mortality in patients with aneurysmal subarachnoid hemorrhage: a nationwide retrospective cohort analysis. Seizure. 2016; 41:66-69

146. Sacco RL, Wolf PA, Bharucha NE, Meeks SL, Kannel WB, Charette LJ et al. Subarachnoid and intracerebral hemorrhage: natural history, prognosis, and precursive factors in the Framingham Study. Neurology. 1984; 34(7):847-854

147. Sahraian S, Beheshtian E, Haj-Mirzaian A, Alvin MD, Yousem DM. "Worst Headache of Life" in a migraineur: marginal value of emergency department CT scanning. Journal of the American College of Radiology. 2019; 16(5):683-690

148. Sare GM, Bath PM, Gray LJ, Moulin T, Woimant F, England T et al. The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST). Stroke. 2009; 40(1):41-46

149. Savitz SI, Edlow J. Thunderclap headache with normal CT and lumbar puncture: further investigations are unnecessary: for. Stroke. 2008; 39(4):1392-1393

150. Sayer D, Bloom B, Fernando K, Jones S, Benton S, Dev S et al. An observational study of 2,248 patients presenting with headache, suggestive of subarachnoid hemorrhage, who received lumbar punctures following normal computed tomography of the head. Academic Emergency Medicine. 2015; 22(11):1267-1273

151. Shimizu Y, Kato H, Lin CH, Kodama K, Peterson AV, Prentice RL. Relationship between longitudinal changes in blood pressure and stroke incidence. Stroke. 1984; 15(5):839-846

152. Sim SY, Song J, Oh SY, Kim MJ, Lim YC, Park SK et al. Incidence and characteristics of remote intracerebral hemorrhage after endovascular treatment of unruptured intracranial aneurysms. World Neurosurgery. 2016; 95:335-340

153. Suthar NN, Patel KL, Saparia C, Parikh AP. Study of clinical and radiological profile and outcome in patients of intracranial hemorrhage. Annals of African Medicine. 2016; 15(2):69-77

154. Suwatcharangkoon S, Meyers E, Falo C, Schmidt JM, Agarwal S, Claassen J et al. Loss of consciousness at onset of subarachnoid hemorrhage as an important marker of early brain injury. JAMA Neurology. 2016; 73(1):28-35

155. Swope R, Glover K, Gokun Y, Fraser JF, Cook AM. Evaluation of headache severity after aneurysmal subarachnoid hemorrhage. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management. 2014; 1(4):119-122

156. Teping F, Albanna W, Clusmann H, Schulze-Steinen H, Mueller M, Hoellig A et al. Spontaneous elevation of blood pressure after SAH: an epiphenomenon of disease severity and demand, but not a surrogate for outcome? Neurocritical Care. 2018; 29(2):214-224

157. Toftdahl DB, Torp-Pedersen C, Engel UH, Strandgaard S, Jespersen B. Hypertension and left ventricular hypertrophy in patients with spontaneous subarachnoid hemorrhage. Neurosurgery. 1995; 37(2):235-239; discussion 239-240

158. Tolias CM, Choksey MS. Will increased awareness among physicians of the significance of sudden agonizing headache affect the outcome of subarachnoid hemorrhage? Coventry and Warwickshire Study: audit of subarachnoid hemorrhage (establishing historical controls), hypothesis, campaign layout, and cost estimation. Stroke. 1996; 27(5):807-812

159. Tsermoulas G, Flett L, Gregson B, Mitchell P. Immediate coma and poor outcome in subarachnoid haemorrhage are independently associated with an aneurysmal origin. Clinical Neurology and Neurosurgery. 2013; 115(8):1362-1365

160. Tsou YJ, Lan KP, Fan JS. Relationship between changes in prehospital blood pressure and early neurological deterioration in spontaneous intracerebral hemorrhage. Advanced Emergency Nursing Journal. 2019; 41(2):163-171

161. Valenca MM, Valenca LP, Menezes TL. Computed tomography scan of the head in patients with migraine or tension-type headache. Arquivos de Neuro-Psiquiatria. 2002; 60(3-A):542-547

162. Valle Alonso J, Fonseca Del Pozo FJ, Vaquero Alvarez M, De la Fuente Carillo JJ, Llamas JC, Hernandez Montes Y. Sudden headache, lumbar puncture, and the diagnosis of subarachnoid hemorrhage in patients with a normal computed tomography scans. Emergencias. 2018; 30(1):50-53

163. Vermeulen MJ, Schull MJ. Missed diagnosis of subarachnoid hemorrhage in the emergency department. Stroke. 2007; 38(4):1216-1221

164. Verweij RD, Wijdicks EF, van Gijn J. Warning headache in aneurysmal subarachnoid hemorrhage. a case-control study. Archives of Neurology. 1988; 45(9):1019-1020

165. Vlak MH, Rinkel GJ, Greebe P, Algra A. Independent risk factors for intracranial aneurysms and their joint effect: a case-control study. Stroke. 2013; 44(4):984-987

166. Wan A, Jaja BNR, Schweizer TA, Macdonald RL. Clinical characteristics and outcome of aneurysmal subarachnoid hemorrhage with intracerebral hematoma. Journal of Neurosurgery. 2016; 125(6):1344-1351

167. Wang J, Alotaibi NM, Akbar MA, Ayling OG, Ibrahim GM, Macdonald RL et al. Loss of consciousness at onset of aneurysmal subarachnoid hemorrhage is associated with functional outcomes in good-grade patients. World Neurosurgery. 2017; 98:308-313

168. Wei SC, Tsai JJ. Bedside diagnosis for neurological residents in neurological emergencies: a retrospective analysis. Chinese Medical Journal. 1994; 53(6):331-337

169. Woo D, Broderick JP. Spontaneous intracerebral hemorrhage: epidemiology and clinical presentation. Neurosurgery Clinics of North America. 2002; 13(3):265-279

170. Wu W, Huo X, Zhao X, Liao X, Wang C, Pan Y et al. Relationship between blood pressure and outcomes in acute ischemic stroke patients administered lytic medication in the TIMS-China study. PloS One. 2016; 11(2):e0144260

171. Ye Z, Ai X, Hu X, Fang F, You C. Clinical features and prognostic factors in patients with intraventricular hemorrhage caused by ruptured arteriovenous malformations. Medicine. 2017; 96(45):e8544

172. Yeh YC, Fuh JL, Chen SP, Wang SJ. Clinical features, imaging findings and outcomes of headache associated with sexual activity. Cephalalgia. 2010; 30(11):1329-1335

173. Yost MD, Rabinstein AA. Spontaneous spinal subarachnoid hemorrhage: presentation and outcome. Journal of Stroke and Cerebrovascular Diseases. 2018; 27(10):2792-2796

174. Yuksen C, Sittichanbuncha Y, Patumanond J, Muengtaweepongsa S, Sawanyawisuth K. Clinical predictive score of intracranial hemorrhage in mild traumatic brain injury. Therapeutics and Clinical Risk Management. 2018; 14:213-218

175. Zia E, Hedblad B, Pessah-Rasmussen H, Berglund G, Janzon L, Engstrom G. Blood pressure in relation to the incidence of cerebral infarction and intracerebral hemorrhage. Hypertensive hemorrhage: debated nomenclature is still relevant. Stroke. 2007; 38(10):2681-2685

176. Zidverc-Trajkovic J, Kovacevic MS, Jovanovic D, Beslac-Bumbasirevic L, Bugarski-Prokopljevic C. Headache as a first symptom of non-traumatic intracerebral hemorrhage. Headache Quarterly. 1998; 9(2):139-143

1 Appendices

2 Appendix A: Review protocols

3 **Table 5: Review protocol: Symptoms and signs for SAH**

ID	Field	Content
0.	PROSPERO registration number	CRD42019160031
1.	Review title	What symptoms and signs indicate subarachnoid haemorrhage?
2.	Review question	What symptoms and signs indicate subarachnoid haemorrhage?
3.	Objective	To determine which symptoms and signs indicate subarachnoid haemorrhage as a possible diagnosis. Review aims to inform diagnosis with signs and symptoms of an initial haemorrhage and subsequent haemorrhages at long-term follow-up.
4.	Searches	The following databases will be searched: • Embase • MEDLINE Searches will be restricted by: • English language only The searches may be re-run 6 weeks before the final committee meeting and further studies retrieved for inclusion if relevant. The full search strategies will be published in the final review.
5.	Condition or domain being studied	Aneurysmal subarachnoid haemorrhage
6.	Population	Inclusion: Adults (16 and older) with a suspected subarachnoid haemorrhage caused by a suspected ruptured aneurysm. Exclusion: • Adults with subarachnoid haemorrhage caused by head injury, ischaemic stroke or an arteriovenous malformation. • Children and young people aged 15 years and younger.
7.	Signs and symptoms	• History of headache (herald/sentinel/prodromal headache) • Sudden severe headache • Painful/stiff neck • Nausea and vomiting • Photophobia • Blurred/double vision • Loss of consciousness

		• Confusional state • Focal neurology (hemiparesis) • Seizure • High blood pressure (>140/90)
8.	Reference standard/ Confounding factors	Reference standard: • confirmed diagnosis of SAH (by CT, LP +/- angiography or post-mortem) Confounding factors: • Age
9.	Types of study to be included	• Prospective and retrospective cohort studies with multivariate analysis will be included preferentially. • Cross-sectional studies Studies will only be included if all the key confounders have been accounted for in a multivariate analysis. In the absence of multivariate analysis, studies that account for key confounders with univariate analysis or matched groups will be considered.
10.	Other exclusion criteria	Exclusions: • Studies that do not account for key confounders. • Non English studies • Conference abstracts
11.	Context	In clinical practice a number of signs and symptoms might indicate that a person has experienced an aneurysmal subarachnoid haemorrhage. An understanding of which signs and symptoms better indicate aSAH as a cause can facilitate further diagnostic investigations to confirm diagnosis and guide treatment.

12.	Primary outcomes (critical outcomes)	Diagnostic association of signs and symptoms with a confirmed diagnosis of aSAH.
		Measured by:
		• Diagnostic accuracy data
		  ○ Sensitivity, specificity, PPV, NPV
		• Association data
		  ○ Adjusted RR or OR.

13.	Secondary outcomes (important outcomes)	n/a
14.	Data extraction (selection and coding)	EndNote will be used for reference management, sifting, citations and bibliographies. All references identified by the searches and from other sources will be screened for inclusion. 10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer. The full text of potentially eligible studies will be retrieved and will be assessed in line with the criteria outlined above.

		A standardised form will be used to extract data from studies (see Developing NICE guidelines: the manual section 6.4).
15.	Risk of bias (quality) assessment	Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual. QUADAS will be used to assess diagnostic association reviews. 10% of all evidence reviews are quality assured by a senior research fellow. This includes checking: • papers were included /excluded appropriately • a sample of the data extractions • correct methods are used to synthesise data • a sample of the risk of bias assessments Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.
16.	Strategy for data synthesis	Aggregate data on diagnostic association of signs and symptoms will be collected and synthesized in a quantitative data analysis. If more than one study covered the same combination of population, sign/symptom and outcome then meta-analysis will be used to pool results. Meta-analysis will be carried out using the generic inverse variance function on Review Manager using fixed effect model. Data synthesis will be completed by two reviewers, with any disagreements resolved by discussion, or if necessary a third independent reviewer. Data from the meta-analysis will be presented and quality assessed in adapted GRADE tables taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each sign/symptom. Publication or other bias will only be taken into consideration in the quality assessment if it is apparent. Heterogeneity between the studies in effect measures will be assessed using the I^2 statistic. We will consider an I^2 value greater than 50% indicative of substantial heterogeneity. We will conduct sensitivity analyses based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented using random effects. If meta-analysis is not possible or appropriate, results will be reported individually per outcome in adapted GRADE tables.

<table>
<tr><td></td><td></td><td colspan="3">Endnote will be used for bibliography, citations, sifting and reference management.</td></tr>
<tr><td>17.</td><td>Analysis of sub-groups</td><td colspan="3">Strata:
• n/a
Subgroups:
• History of SAH
  ○ Personal previous SAH
  ○ No history of SAH
  ○ Familial history of SAH</td></tr>
<tr><td rowspan="8">18.</td><td rowspan="8">Type and method of review</td><td>☐</td><td colspan="2">Intervention</td></tr>
<tr><td>☒</td><td colspan="2">Diagnostic</td></tr>
<tr><td>☐</td><td colspan="2">Prognostic</td></tr>
<tr><td>☐</td><td colspan="2">Qualitative</td></tr>
<tr><td>☐</td><td colspan="2">Epidemiologic</td></tr>
<tr><td>☐</td><td colspan="2">Service Delivery</td></tr>
<tr><td>☒</td><td colspan="2">Other (diagnostic association)</td></tr>
<tr><td></td><td></td></tr>
<tr><td>19.</td><td>Language</td><td colspan="3">English</td></tr>
<tr><td>20.</td><td>Country</td><td colspan="3">England</td></tr>
<tr><td>21.</td><td>Anticipated or actual start date</td><td colspan="3"></td></tr>
<tr><td>22.</td><td>Anticipated completion date</td><td colspan="3">3 February 2021</td></tr>
<tr><td rowspan="8">23.</td><td rowspan="8">Stage of review at time of this submission</td><td>Review stage</td><td>Started</td><td>Completed</td></tr>
<tr><td>Preliminary searches</td><td>☑</td><td>☑</td></tr>
<tr><td>Piloting of the study selection process</td><td>☑</td><td>☑</td></tr>
<tr><td>Formal screening of search results against eligibility criteria</td><td>☑</td><td>☑</td></tr>
<tr><td>Data extraction</td><td>☑</td><td>☑</td></tr>
<tr><td>Risk of bias (quality) assessment</td><td>☑</td><td>☑</td></tr>
<tr><td>Data analysis</td><td>☑</td><td>☑</td></tr>
<tr><td></td><td></td><td></td></tr>
<tr><td>24.</td><td>Named contact</td><td colspan="3">5a. Named contact
National Guideline Centre

5b Named contact e-mail
SAH@nice.org.uk

5e Organisational affiliation of the review</td></tr>
</table>

		National Institute for Health and Care Excellence (NICE) and the National Guideline Centre
25.	Review team members	From the National Guideline Centre: • Ms Gill Ritchie • Mr Ben Mayer • Mr Audrius Stonkus • Mr Vimal Bedia • Ms Emma Cowles • Ms Elizabeth Pearton • Ms Jill Cobb • Ms Amelia Unsworth
26.	Funding sources/sponsor	This systematic review is being completed by the National Guideline Centre which receives funding from NICE.
27.	Conflicts of interest	All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.
28.	Collaborators	Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of Developing NICE guidelines: the manual. Members of the guideline committee are available on the NICE website.
29.	Other registration details	
30.	Reference/URL for published protocol	
31.	Dissemination plans	NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as: • notifying registered stakeholders of publication • publicising the guideline through NICE's newsletter and alerts • issuing a press release or briefing as appropriate, posting news articles on the

		NICE website, using social media channels, and publicising the guideline within NICE.	
32.	Keywords	Subarachnoid haemorrhage; symptoms; signs	
33.	Details of existing review of same topic by same authors	None	
34.	Current review status	☐	Ongoing
		☐	Completed but not published
		☐	Completed and published
		☐	Completed, published and being updated
		☐	Discontinued
35..	Additional information		
36.	Details of final publication	www.nice.org.uk	

1

2 **Table 6: Health economic review protocol**

Review question	All questions where health economic evidence applicable
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	• Populations, interventions and comparators must be as specified in the clinical review protocol above. • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter.
Review strategy	Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded. Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual.[112] **Inclusion and exclusion criteria** • If a study is rated as both 'Directly applicable' and with 'Minor limitations' then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile. • If a study is rated as either 'Not applicable' or with 'Very serious limitations' then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile. • If a study is rated as 'Partially applicable', with 'Potentially serious limitations' or both then there is discretion over whether it should be included.

Where there is discretion

The health economist will decide based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded based on applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

Setting:

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

Year of analysis:

- The more recent the study, the more applicable it will be.
- Studies published in 2003 or later but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as 'Not applicable'.
- Studies published before 2003 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

Appendix B: Literature search strategies

This literature search strategy was used for the following review;

- What symptoms and signs indicate subarachnoid haemorrhage?

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual[112]

For more information, please see the Methods Report published as part of the accompanying documents for this guideline.

B.11 Clinical search literature search strategy

Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.

Table 7: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 23 June 2020	Exclusions Observational studies
Embase (OVID)	1974 – 23 June 2020	Exclusions Observational studies

Medline (Ovid) search terms

1.	exp Subarachnoid Hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracerebral or intra-cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	Intracranial Aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracerebral or intra-cerebral or intracranial or intra-cranial or brain) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter/
8.	editorial/
9.	news/
10.	exp historical article/
11.	Anecdotes as Topic/
12.	comment/
13.	case report/
14.	(letter or comment*).ti.
15.	or/7-14
16.	randomized controlled trial/ or random*.ti,ab.
17.	15 not 16
18.	animals/ not humans/
19.	exp Animals, Laboratory/
20.	exp Animal Experimentation/
21.	exp Models, Animal/
22.	exp Rodentia/
23.	(rat or rats or mouse or mice).ti.
24.	or/17-23
25.	6 not 24
26.	(exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/)
27.	25 not 26
28.	limit 27 to English language

29.	exp "signs and symptoms"/
30.	Symptom Assessment/
31.	diagnosis/ or prognosis/
32.	(clinical adj2 (manifestation* or feature* or finding* or aspect* or marker* or present*)).ti,ab.
33.	(present* adj2 (feature* or finding* or factor*)).ti,ab.
34.	(physical adj2 (manifestation* or characteristic* or feature* or finding*)).ti,ab.
35.	(sign or signs or symptom* or recogni* or identif* or complain*).ti,ab.
36.	(diagnos* or prognos* or assess* or criteria* or predict*).ti,ab.
37.	or/29-36
38.	*Headache/ or *headache disorders/ or *migraine disorders/
39.	(headache* or migraine*).ti,ab.
40.	(head adj3 pain*).ti,ab.
41.	((pain* or stiff*) adj2 neck*).ti,ab.
42.	*Vomiting/
43.	(vomit* or emesis or emeses or sick or sickness or nausea).ti,ab.
44.	*Blood Pressure/
45.	(blood adj2 pressure).ti,ab.
46.	*Unconsciousness/
47.	(consciousness or unconsciousness or semiconsciousness or semi consciousness).ti,ab.
48.	*Delirium/ or *Confusion/
49.	(delirium* or deliria or confus*).ti,ab.
50.	((alter* or chang*) adj2 mental state*).ti,ab.
51.	*Seizures/
52.	(spasm* or seizure* or convuls*).ti,ab.
53.	*paresis/ or *paraparesis/
54.	(hemipares* or monopares* or paresis or pareses or parapares* or plegia* or hemiplegia* or paraplegia* or paralys* or palsy).ti,ab.
55.	(focal adj2 (neurolog* or sign* or deficit)).ti,ab.
56.	(impair* adj2 (brain or neurolog* or nerve* or nervous system* or spine or spinal)).ti,ab.
57.	(weak* adj2 (arm* or leg* or limb* or body or muscle*)).ti,ab.
58.	*Photophobia/
59.	Photophobi*.ti,ab.
60.	((sensitiv* or intoleran* or pain* or discomfort) adj2 light).ti,ab.
61.	*Diplopia/
62.	diplopia.ti,ab.
63.	((double or blur* or hazy or altered or change* or loss) adj3 vision).ti,ab.
64.	or/38-63
65.	28 and (37 or 64)
66.	Epidemiologic studies/
67.	Observational study/
68.	exp Cohort studies/
69.	(cohort adj (study or studies or analys* or data)).ti,ab.
70.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.

71.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
72.	Controlled Before-After Studies/
73.	Historically Controlled Study/
74.	Interrupted Time Series Analysis/
75.	(before adj2 after adj2 (study or studies or data)).ti,ab.
76.	exp case control study/
77.	case control*.ti,ab.
78.	Cross-sectional studies/
79.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
80.	or/66-79
81.	65 and 80

1 **Embase (Ovid) search terms**

1.	*subarachnoid hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp intracranial aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter.pt. or letter/
8.	note.pt.
9.	editorial.pt.
10.	Case report/ or Case study/
11.	(letter or comment*).ti.
12.	or/7-11
13.	randomized controlled trial/ or random*.ti,ab.
14.	12 not 13
15.	animal/ not human/
16.	Nonhuman/
17.	exp Animal Experiment/
18.	exp Experimental animal/
19.	Animal model/
20.	exp Rodent/
21.	(rat or rats or mouse or mice).ti.
22.	or/14-21
23.	6 not 22
24.	(exp child/ or exp pediatrics/) not (exp adult/ or exp adolescent/)
25.	23 not 24
26.	limit 25 to English language
27.	symptom assessment/
28.	diagnosis/
29.	prognosis/

30.	(clinical adj2 (manifestation* or feature* or finding* or aspect* or marker* or present*)).ti,ab.
31.	(present* adj2 (feature* or finding* or factor*)).ti,ab.
32.	(physical adj2 (manifestation* or characteristic* or feature* or finding*)).ti,ab.
33.	(sign or signs or symptom* or recogni* or identif* or complain*).ti,ab.
34.	(diagnos* or prognos* or assess* or criteria* or predict*).ti,ab.
35.	symptomatology/
36.	or/27-35
37.	*headache/
38.	*migraine/
39.	(headache* or migraine*).ti,ab.
40.	(head adj3 pain*).ti,ab.
41.	*neck pain/
42.	((pain* or stiff*) adj2 neck*).ti,ab.
43.	*vomiting/
44.	(vomit* or emesis or emeses or sick or sickness or nausea).ti,ab.
45.	*Blood Pressure/
46.	(blood adj2 pressure).ti,ab.
47.	*consciousness/
48.	(consciousness or unconsciousness or semiconsciousness or semi consciousness).ti,ab.
49.	*delirium/
50.	*confusion/
51.	(delirium* or deliria or confus*).ti,ab.
52.	((alter* or chang*) adj2 mental state*).ti,ab.
53.	*seizure/
54.	(spasm* or seizure* or convuls*).ti,ab.
55.	*paresis/
56.	*paraplegia/
57.	(hemipares* or monopares* or paresis or pareses or parapares* or plegia* or hemiplegia* or paraplegia* or paralys* or palsy).ti,ab.
58.	(focal adj2 (neurolog* or sign* or deficit)).ti,ab.
59.	(impair* adj2 (brain or neurolog* or nerve* or nervous system* or spine or spinal)).ti,ab.
60.	(weak* adj2 (arm* or leg* or limb* or body or muscle*)).ti,ab.
61.	*paralysis/
62.	*Photophobia/
63.	Photophobi*.ti,ab.
64.	((sensitiv* or intoleran* or pain* or discomfort) adj2 light).ti,ab.
65.	*Diplopia/
66.	diplopia.ti,ab.
67.	((double or blur* or hazy or altered or change* or loss) adj3 vision).ti,ab.
68.	or/37-67
69.	26 and (36 or 68)
70.	Clinical study/
71.	Observational study/
72.	family study/

73.	longitudinal study/
74.	retrospective study/
75.	prospective study/
76.	cohort analysis/
77.	follow-up/
78.	cohort*.ti,ab.
79.	77 and 78
80.	(cohort adj (study or studies or analys* or data)).ti,ab.
81.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
82.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
83.	(before adj2 after adj2 (study or studies or data)).ti,ab.
84.	exp case control study/
85.	case control*.ti,ab.
86.	cross-sectional study/
87.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
88.	or/70-76,79-87
89.	69 and 88

1

B.2 Health Economics literature search strategy

Health economic evidence was identified by conducting a broad search relating to subarachnoid haemorrhage population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional searches were run on Medline and Embase.

Table 8: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline	2003 – 23 June 2020	Exclusions Health economics studies
Embase	2003 – 23 June 2020	Exclusions Health economics studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 23 June 2020 NHSEED - Inception to March 2015	None

Medline (Ovid) search terms

1.	exp Subarachnoid Hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp Intracranial Aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter/
8.	editorial/
9.	news/
10.	exp historical article/
11.	Anecdotes as Topic/
12.	comment/
13.	case report/
14.	(letter or comment*).ti.
15.	or/7-14
16.	randomized controlled trial/ or random*.ti,ab.
17.	15 not 16
18.	animals/ not humans/
19.	exp Animals, Laboratory/
20.	exp Animal Experimentation/
21.	exp Models, Animal/
22.	exp Rodentia/
23.	(rat or rats or mouse or mice).ti.
24.	or/17-23

25.	6 not 24
26.	limit 25 to English language
27.	Economics/
28.	Value of life/
29.	exp "Costs and Cost Analysis"/
30.	exp Economics, Hospital/
31.	exp Economics, Medical/
32.	Economics, Nursing/
33.	Economics, Pharmaceutical/
34.	exp "Fees and Charges"/
35.	exp Budgets/
36.	budget*.ti,ab.
37.	cost*.ti.
38.	(economic* or pharmaco?economic*).ti.
39.	(price* or pricing*).ti,ab.
40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
41.	(financ* or fee or fees).ti,ab.
42.	(value adj2 (money or monetary)).ti,ab.
43.	or/27-42
44.	26 and 43

1 **Embase (Ovid) search terms**

1.	subarachnoid hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp intracranial aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter.pt. or letter/
8.	note.pt.
9.	editorial.pt.
10.	case report/ or case study/
11.	(letter or comment*).ti.
12.	or/7-11
13.	randomized controlled trial/ or random*.ti,ab.
14.	12 not 13
15.	animal/ not human/
16.	nonhuman/
17.	exp Animal Experiment/
18.	exp Experimental Animal/
19.	animal model/
20.	exp Rodent/

21.	(rat or rats or mouse or mice).ti.
22.	or/14-21
23.	6 not 22
24.	limit 23 to English language
25.	health economics/
26.	exp economic evaluation/
27.	exp health care cost/
28.	exp fee/
29.	budget/
30.	funding/
31.	budget*.ti,ab.
32.	cost*.ti.
33.	(economic* or pharmaco?economic*).ti.
34.	(price* or pricing*).ti,ab.
35.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
36.	(financ* or fee or fees).ti,ab.
37.	(value adj2 (money or monetary)).ti,ab.
38.	or/25-37
39.	24 and 38

1 **NHS EED and HTA (CRD) search terms**

#1.	MeSH DESCRIPTOR Subarachnoid Hemorrhage EXPLODE ALL TREES
#2.	MeSH DESCRIPTOR Intracranial Hemorrhages EXPLODE ALL TREES
#3.	(((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)))
#4.	((SAH or aSAH))
#5.	#1 OR #2 OR #3 OR #4
#6.	MeSH DESCRIPTOR Aneurysm EXPLODE ALL TREES
#7.	((aneurysm* or hematoma* or haematoma*))
#8.	#6 OR #7
#9.	MeSH DESCRIPTOR Intracranial Aneurysm EXPLODE ALL TREES
#10.	(((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (aneurysm* or hematoma* or haematoma*)))
#11.	#9 OR #10
#12.	MeSH DESCRIPTOR Aneurysm, ruptured
#13.	(((ruptur* or weak* or brain or trauma*) adj3 (aneurysm* or hematoma* or haematoma*)))
#14.	#12 OR #13
#15.	(#5 or #8 or #11 or #14)

2

3

Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the review of symptoms and signs for SAH



Appendix D: Clinical evidence tables

Reference	Kelly 2014[55]
Study type and analysis	Retrospective multi-centre cohort study The estimated sensitivity for subarachnoid haemorrhage, including 95% CIs, were calculated for the clinical decision rules. Potential cases were identified from the ED data management database by final ED diagnosis of 'subarachnoid haemorrhage, non-traumatic' or 'haemorrhage, intracranial, nontraumatic'.
Number of participants and characteristics	N= 59 Inclusion: Cases were adult patients aged greater than 16 years with confirmed SAH presenting to the ED of two community teaching hospitals without specialist neurosurgical units in Melbourne, Australia, between 2000 and 2011. Exclusion: Patients were excluded if they were aged <16 years, had a history of trauma within the last 7 days (collapse associated with onset of headache leading to head injury was not an exclusion), history of previous SAH, known cerebral aneurysm or cerebral neoplasm, it was more than 14 days from symptom onset, there was absence of 'sudden' headache, there was a history of three or more headaches with similar characteristics and intensity over more than 6 months, GCS was <15, there were new focal neurological signs or there was failure to confirm the diagnosis of SAH by CT head scan, CT angiography, conventional angiography, MRI or LP supported by specialist neurosurgical opinion.
Diagnostic variable(s)	• Complaint of neck pain or stiffness • Onset with exertion • Witnessed loss of consciousness • Arrival by ambulance • Vomited at least once • Diastolic blood pressure >100 mmHg • Systolic BP >160 mmHg • Age >40 years • Age >45 years • Age 45-55 years

Reference	Kelly 2014[55]			
Clinical Decision Rules	Rule 1 1. Age ≥40 y 2. Neck pain or stiffness 3. Witnessed loss of consciousness 4. Onset during exertion Investigate if ≥1 high-risk findings present: Rule 2 1. Age ≥ 45 y 2. Arrival by ambulance 3. Vomiting (≥1 episodes) 4. Diastolic blood pressure ≥100mmHg Investigate if ≥1 high-risk findings present: Rule 3 1. Age 45-55 y 2. Neck pain or stiffness 3. Arrival by ambulance 4. Systolic blood pressure ≥160mmHg			
Reference standard	Reference standard: Diagnosis of SAH by CT head scan, CT angiography, conventional angiography, MRI or LP supported by specialist neurosurgical opinion. Follow-up: <14 days from symptom onset			
Outcomes and effect sizes: CDR		Rule 1	Rule 2	Rule 3
	True Positive	57	59	53
	False Positive	NA	NA	NA
	False Negative	2	0	6
	True Negative	NA	NA	NA
	Sensitivity	96.6% (95% CI 88.5–99.1%)	100% (95% CI 93.9–100%)	89.8% (95% CI 79.5–95.3%)
	Specificity	NA	NA	NA

Reference	Kelly 2014[55]			
	Negative predictive value	NA	NA	NA
Outcomes and effect sizes: Signs and symptoms	Sign/symptom	True positive	False Negative	Sensitivity
	Complaint of neck pain or stiffness	25	34	42.4%
	Onset with exertion	12	47	20.3%
	Witnessed loss of consciousness	11	48	18.6%
	Arrival by ambulance	41	18	69.5%
	Vomited at least once	39	20	66.1%
	Diastolic blood pressure >100 mmHg	6	53	10.2%
	Systolic BP >160 mmHg	18	41	30.5%
	Age >40 years	47	12	79.6%
	Age >45 years	41	18	69.5%
	Age 45-55 years	16	43	27.1%
Comments	Cohort only included confirmed SAH cases. Only sensitivity available.			
Risk of Bias	High risk of bias This was given due potential bias around the selection of participants and index test with (a) selective analysis of only participants with confirmed SAH (b) a lack of clarity regarding the application of the variables within the clinical decision rule. There were no concerns regarding applicability.			

1

Reference	Mark 2015[97]
Study type and analysis	Retrospective multicentre cohort study The estimated sensitivity, for subarachnoid haemorrhage, including 95% CIs, were calculated for the clinical decision rule.
Number of participants and characteristics	N= 155 Inclusion: Patients who had an ED or hospital encounter with an associated International Statistical Classification of Diseases and Related Health Problems, ninth edition (ICD-9) diagnosis code of SAH between January 2007 and June 2013. Hunt-Hess clinical grade

Reference	Mark 2015[97]	
	of 1 or 2 at the time of ED presentation, non-contrast cranial CT imaging within six hours of headache onset, either evidence of SAH on non-contrast cranial CT or greater than five red blood cells per microliter on cerebrospinal fluid analysis, and angiographic evidence of cerebral aneurysm thought to be consistent with the clinical presentation and pattern of haemorrhage visualized on imaging, if applicable. Exclusion: Patients were electronically excluded if they had an ICD-9 coded diagnosis of head or neck trauma within 24 hours of the index encounter, lacked continuous KFHP membership within the two weeks preceding diagnosis, were under 18 years of age or had a prior diagnosis of SAH Consecutive adult patients from the emergency departments of 10 university-affiliated urban Canadian tertiary care teaching hospitals from April 2006 to July 2010.	
Diagnostic variable(s)	1. Age ≥40 y 2. Neck pain or stiffness 3. Witnessed loss of consciousness 4. Onset during exertion A negative result being defined as absence of all four clinical criteria.	
Reference standard	SAH Reference standard: Evidence of SAH on non-contrast cranial CT or >5 RBC per microliter on CSF analysis, and angiographic evidence of cerebral aneurysm thought to be consistent with clinical presentation and pattern of haemorrhage visualised on imaging. All CT examinations were performed without contrast using multi-slice cine technology (16 slice or higher). Either general radiologists or neuroradiologists made the final interpretation of CT images Follow-up: CT performed <6 hours from symptom onset. Timing of alternative investigation unclear	
Outcomes and effect sizes		
	True Positive	148/155
	False Positive	NA
	False Negative	7/155
	True Negative	NA
	Sensitivity	95.5% (95% CI [90.9-98.2]
	Specificity	NA
	Negative predictive value	NA

Reference	Mark 2015[97]
Comments	Cohort only included confirmed SAH cases. Only sensitivity available.
Risk of Bias	Moderate risk of bias This was given due potential bias around the selection of participants with a selective analysis of only participants with confirmed SAH. There were no concerns regarding applicability.

1

Reference	Pathan 2018[130]	
Study type and analysis	Retrospective cohort study The estimated sensitivity and specificity for subarachnoid haemorrhage, including 95% CIs, were calculated for the Ottawa rule.	
Number of participants and characteristics	N= 145 Inclusion: All patients registered with a primary complaint of a headache from 1st January 2016 to 31st December 2016 were identified. Age older than 15 years, new atraumatic headache, and headaches that reached maximal intensity in 1 hour Exclusion: Any new neurological deficits, prior diagnosis of cerebral aneurysms/SAH/brain tumours, and those with recurrent headaches in last 6 months	
Stratification strategy	Ottawa Rule	
	For alert patients olderthan15 years with new severe non-traumatic headache reaching maximum intensity within 1 h Investigate if ≥1 high-risk variables present: 1. Age ≥40 y 2. Neck pain or stiffness 3. Witnessed loss of consciousness 4. Onset during exertion 5. Thunderclap headache (instantly peaking pain) 6. Limited neck flexion on examination	
Reference standard	Reference standard: subarachnoid blood visible on a plain CT film or xanthochromia in the cerebrospinal fluid. Follow-up: unclear	
Outcomes and effect sizes		Ottawa Rule
	True Positive	5

Reference	Pathan 2018[130]	
	False Positive	78
	False Negative	0
	True Negative	62
	Sensitivity	100% (95% CI 46.3 % - 100 %)
	Specificity	44.2 % (95% CI, 36 % - 53 %)
	Negative predictive value	100%
Risk of Bias	Moderate risk of bias This was given due potential bias around the reference standard with not all patients having the reference test. There were no concerns regarding applicability.	

1

2

3

Reference	Perry 2013[132] merged with Perry 2010[133]
Study type and analysis	Prospective multi-centre cohort study Multivariate recursive partitioning analysis. The estimated sensitivity, specificity, and C statistic for subarachnoid haemorrhage, including 95% CIs, were calculated for the refined rule.
Number of participants and characteristics	N= 2131 Inclusion: Consecutive adult patients from the emergency departments of 10 university-affiliated urban Canadian tertiary care teaching hospitals from April 2006 to July 2010. Adult patients (defined as patients 16 years or older) whose chief reason for visiting the emergency department was a non-traumatic headache that reached maximal intensity within 1 hour were considered for enrolment. We enrolled patients who had a Glasgow Coma Scale score of 15 of 15 (i.e., alert and oriented), had not sustained a fall or direct head trauma in the previous 7 days, and who had presented within 14 days of headache onset Exclusion: Patients were ineligible if they had a history of 3 or more recurrent headaches of the same character and intensity as the presenting headache over a period greater than 6 months (i.e., established recurrent headache syndromes); were referred from another hospital with a confirmed subarachnoid haemorrhage; returned for reassessment of the same headache if already investigated with both CT and lumbar puncture; had papilledema on funduscopic examination (as determined by the treating physician); had new

Reference	Perry 2013[132] merged with Perry 2010[133]
	focal neurologic deficits (e.g., isolated cranial nerve palsies, limb weakness); or had a previous diagnosis of cerebral aneurysm, subarachnoid haemorrhage, brain neoplasm, or hydrocephalus.
Diagnostic variable(s)	• Arrived by ambulance • Time from peak onset • Pain severity at peak • Onset during exertion • Onset during sexual activity • Headache awoke patient from sleep • Thunderclap headache • Reported worse headache of life • Loss of consciousness • Neck pain or stiffness • Vomiting • Able to walk since headache • Emergency department transfer • Limited flexion • Heart rate • Blood pressure • Temperature • CT obtained • Lumbar Puncture
Reference standard	SAH Reference standard: subarachnoid blood on unenhanced CT of the head; xanthochromia in the cerebrospinal fluid; or red blood cells (>1 × 106/L) in the final tube of cerebrospinal fluid, with an aneurysm or arteriovenous malformation on cerebral angiography. This outcome was established a priori by consensus of 5 emergency physicians and 1 neurosurgeon. Follow-up: Timing of CT/LP relative to symptom onset unclear. Patients discharged without both CT imaging and normal lumbar puncture findings (or without both CT imaging and lumbar puncture performed) were evaluated using a structured telephone interview

Reference	Perry 2013[132] merged with Perry 2010[133]					
	at 1 month and 6 months after emergency department assessment as well as a medical records review to identify any patients who developed a subsequent subarachnoid haemorrhage.					
Stratification strategy	Rule 1	Rule 2	Rule 3	Ottawa Rule		
	Investigate if ≥1 high-risk findings present: 1. Age ≥40 y 2. Neck pain or stiffness 3. Witnessed loss of consciousness 4. Onset during exertion	Investigate if ≥1 high-risk findings present: 1. Age ≥ 45 y 2. Arrival by ambulance 3. Vomiting (≥1 episodes) 4. Diastolic blood pressure ≥100mmHg	Investigate if ≥1 high-risk findings present: 1. Age 45-55 y 2. Neck pain or stiffness 3. Arrival by ambulance 4. Systolic blood pressure ≥160mmHg	For alert patients olderthan15 years with new severe non-traumatic headache reaching maximum intensity within 1 h Investigate if ≥1 high-risk variables present: 1. Age ≥40 y 2. Neck pain or stiffness 3. Witnessed loss of consciousness 4. Onset during exertion 5. Thunderclap headache (instantly peaking pain) 6. Limited neck flexion on examination		
Outcomes and effect sizes		Rule 1	Rule 2	Rule 3	Ottawa Rule	
	True Positive	130	126	128	132	
	False Positive	1447	1287	1388	1694	
	False Negative	2	6	4	0	
	True Negative	552	712	611	305	
	Sensitivity	98.5% (94.6-99.6)	95.5% (90.4-97.9)*	97.0% (92.5-98.8)*	100% (97.2-100)	
	Specificity	27.6% (25.7-29.6)	30.6% (28.6-32.6)	35.6% (33.6-37.7)	15.3% (13.8-16.9)	
	Negative predictive value	99.6%	99.0%	99.4%	100%	
	Sign/symptom	True positive	False Positive	True negative	False Negative	Sensitivity	Specificity
	Arrived by ambulance	81	478	1521	51	61.40%	76.10%
	Onset during exertion	25	206	1793	107	19.20%	89.70%

Reference	Perry 2013[132] merged with Perry 2010[133]						
	Onset during sexual activity	13	124	1875	119	9.80%	93.80%
	Headache awoke patient from sleep	16	348	1651	116	12.10%	82.60%
	Thunderclap headache	109	1093	906	23	82.40%	45.30%
	Worst headache of life	131	1511	488	1	99.20%	24.40%
	Loss of consciousness	14	106	1893	118	10.60%	94.70%
	Loss of consciousness (witnessed)	7	72	1927	125	5.30%	96.40%
	Neck pain or stiffness	101	632	1367	31	76.50%	68.40%
	Vomiting	87	528	1471	45	65.90%	73.60%
	Able to walk since headache	101	1801	198	31	76.60%	9.90%
	Emergency department transfer	22	162	1837	110	16.70%	91.90%
	Limited flexion	37	64	1935	95	28.30%	96.80%
Comments	*Analysis reported in article differ from analysis from forest plots (sensitivity for Rule 2 - 97.0% and sensitivity for Rule 3 – 95.5%)						
Risk of Bias	Moderate risk of bias This was given due potential bias around the reference standard with not all patients having the reference test. There were no concerns regarding applicability.						

1

1 Appendix E: Forest plots

E.1 2 Signs & Symptoms

Figure 2: Diagnostic accuracy for clinical decision rules for detecting SAH



3 **Figure 3: Diagnostic accuracy for individual signs and symptoms for detecting SAH**

Arrived by ambulance

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Kelly 2014	41	0	18	0	0.69 [0.56, 0.81]	Not estimable
Perry 2013	81	478	51	1521	0.61 [0.52, 0.70]	0.76 [0.74, 0.78]



Onset during exertion

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Kelly 2014	21	0	47	0	0.31 [0.20, 0.43]	Not estimable
Perry 2013	25	206	107	1793	0.19 [0.13, 0.27]	0.90 [0.88, 0.91]



Onset during sexual activity

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Perry 2013	13	124	119	1875	0.10 [0.05, 0.16]	0.94 [0.93, 0.95]



Headache awoke patient from sleep

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Perry 2013	16	348	116	1651	0.12 [0.07, 0.19]	0.83 [0.81, 0.84]



Thunderclap headache

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Perry 2013	109	1093	23	906	0.83 [0.75, 0.89]	0.45 [0.43, 0.48]



Worst headache of life

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Perry 2013	131	1511	1	488	0.99 [0.96, 1.00]	0.24 [0.23, 0.26]



Loss of consciousness

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Perry 2013	14	106	118	1893	0.11 [0.06, 0.17]	0.95 [0.94, 0.96]



Loss of consciousness (witnessed)

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Kelly 2014	11	0	48	0	0.19 [0.10, 0.31]	Not estimable
Perry 2013	7	72	125	1927	0.05 [0.02, 0.11]	0.96 [0.95, 0.97]



Neck pain or stiffness

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Kelly 2014	25	0	34	0	0.42 [0.30, 0.56]	Not estimable
Perry 2013	101	632	6670	1367	0.01 [0.01, 0.02]	0.68 [0.66, 0.70]



Vomiting

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Kelly 2014	39	0	20	0	0.66 [0.53, 0.78]	Not estimable
Perry 2013	87	528	45	1471	0.66 [0.57, 0.74]	0.74 [0.72, 0.76]



Able to walk since headache

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Perry 2013	101	1801	31	198	0.77 [0.68, 0.83]	0.10 [0.09, 0.11]



Emergency department transfer

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Perry 2013	22	162	110	1837	0.17 [0.11, 0.24]	0.92 [0.91, 0.93]



Limited flexion

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Perry 2013	37	64	95	1935	0.28 [0.21, 0.37]	0.97 [0.96, 0.98]



Diastolic BP >100mmHg

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Kelly 2014	6	0	53	0	0.10 [0.04, 0.21]	Not estimable



Systolic BP >160 mmHg

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Kelly 2014	18	0	41	0	0.31 [0.19, 0.44]	Not estimable



Age >40 years

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Kelly 2014	47	0	12	0	0.80 [0.67, 0.89]	Not estimable



Age >45 years

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Kelly 2014	41	0	18	0	0.69 [0.56, 0.81]	Not estimable



Age 45-55 years

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Kelly 2014	16	0	43	0	0.27 [0.16, 0.40]	Not estimable



1

2

Appendix F:Health economic evidence selection

Figure 4: Flow chart of health economic study selection for the guideline



* Non-relevant population, intervention, comparison, design or setting; non-English language

1

Appendix G: Health economic evidence tables

None.

1 Appendix H: Excluded studies

H.1 2 Excluded clinical studies

3 **Table 9: Studies excluded from the clinical review**

Reference	Reason for exclusion
Acuna 2011[1]	Inappropriate analysis – incidence of symptoms
Alimohamadi 2016[2]	Inappropriate review focus– effect of electrolyte imbalance in SAH
Ariesen 2003[3]	Systematic review – references checked
Arima 2012[4]	Inappropriate study design – interventional study
Arima 2012[5]	No relevant outcomes
Asari 1993[6]	Inappropriate study design – prognostic risk factors for SAH
Backes 2015[8]	No relevant outcomes
Backes 2016[7]	Inappropriate population – patients with unruptured aneurysms
Bassi 1991[9]	Inappropriate comparison – symptoms in diagnosed and misdiagnosed SAH
Bhat 2011[10]	Inappropriate study design – No relevant outcomes
Bijlenga 2017[11]	Inappropriate study design – screening tool assessment
Bolouki 2019[12]	Inappropriate review focus– predictors of hospital mortality in SAH patients
Bonilha 2001[13]	Inappropriate study design – No relevant outcomes
Breen 2008[14]	Inappropriate analysis/no usable outcome data – proportion of patients with SAH and headache
Canhao 1999[15]	Inappropriate study design/review focus – prognostic risk factors for SAH
Chertcoff 2017[16]	No usable outcome – aetiology of confirmed cases of convexity subarachnoid haemorrhage
Cho 2016[17]	Inappropriate population – majority of included patients children
Donnan 1994[18]	Inappropriate study design – literature review
Duan 2018[19]	Inappropriate study design – risk factors for DCI
Ellamushi 2001[20]	Inappropriate study design – risk factors for multiple aneurysms
Feigin 2005[21]	Systematic review – references checked
Fogelholm 1993[22]	Inappropriate study design/review focus – smoking as a prognostic risk factor
Fogelholm 1987[23]	Inappropriate study design/review focus – smoking as a prognostic risk factor
Foreman 2018[24]	Inappropriate study design – No relevant outcomes
Fridriksson 2001[25]	Inappropriate review focus – long term prognostic risk factors
Garbe 2013[26]	Inappropriate review focus – long term prognostic risk factors
Giordan 2018[27]	Inappropriate population – unruptured intracranial aneurysms
Giroud 1995[28]	Inappropriate review focus – long term prognostic risk factors
Greving 2014[29]	Systematic review – references checked
Gu 2006[30]	Inappropriate review focus – long term prognostic risk factors
Guo 2011[31]	Inappropriate review focus – long term prognostic risk factors for early re-bleeding
Ha 2011[32]	Inappropriate review focus – factors affecting surgical outcomes of proximal middle

Reference	Reason for exclusion
	cerebral artery aneurysms
Haffaf 2019[33]	Inappropriate review population – majority of patients with unruptured aneurysms
Hamann 1995[34]	Inappropriate review population – raised urine catecholamine
Hamdan 2014[35]	Inappropriate review focus – long term prognostic risk factors
Han 2017[36]	Inappropriate population – traumatic brain injury
Hanefeld 2018[37]	Inappropriate study design – No relevant outcomes
Harmsen 1990[38]	Inappropriate review focus – long term prognostic risk factors
Hatcher 2017[39]	Inappropriate study design – No relevant outcomes
Hauerberg 1991[40]	No relevant outcome – patients with warning leak prior to SAH
Hillen 2003[41]	Inappropriate study design – No relevant outcomes
Honig 2015[42]	Inappropriate review population – fever
Hylleraas 2010[43]	Inappropriate population – headache in people without SAH
Inamasu 2015[44]	No usable outcome – BP on admission
Inamasu 2015[45]	Inappropriate review comparison – chronic hypertension compared to admission BP in SAH
Ivan 2019[46]	No relevant outcome – aneurysm characteristics
Jabbarli 2018[47]	Inappropriate review focus – long term prognostic risk factors
Jabbarli 2020[48]	Systematic review - references checked
Jakobsson 1996[49]	No relevant outcome – potential leaks prior to SAH
Jerntorp 1992[50]	Inappropriate study design/ No relevant outcomes
Jiang 2016[51]	No relevant outcome – aneurysm characteristics
Juvela 1995[52]	No relevant outcome – association of DCI with aspirin in SAH
Kann 1997[53]	Inappropriate review focus – carotid artery disease in ICH patients
Katz 2009[54]	Inappropriate study design/ No relevant outcomes
Khan 2017[56]	Inappropriate review focus – comparing timing of CT scan
Kim 1999[58]	Inappropriate population – stroke
Kim 2018[57]	Inappropriate population – head injury patients
Kinnecom 2007[59]	Inappropriate population – cerebral amyloid angiopathy
Kleinpeter 2003[60]	Inappropriate review focus – long term prognostic risk factors
Koivunen 2015[61]	Inappropriate population – intracerebral haemorrhage
Konczalla 2014[62]	Inappropriate study design – No relevant outcomes
Koopman 2019[63]	Inappropriate study design/ No relevant outcomes
Korja 2013[64]	Inappropriate review focus – long term prognostic risk factors
Koshy 2010[65]	Inappropriate review focus – long term prognostic risk factors
Kumral 1999[66]	Inappropriate population – caudate stroke
Lacey 2018[67]	Inappropriate study design/ No relevant outcomes
Lai 2014[68]	Inappropriate study design/ No relevant outcomes
Lansley 2016[69]	Inappropriate comparison – comparison of assessment for SAH between clinicians and neurospecialists
Le Roux 1998[70]	Inappropriate review focus – angiography after surgery
Le Roux 1996[71]	Inappropriate study design – No relevant outcomes
Leira 2005[72]	No relevant outcome – headache and cavity volume
Lepojarvi 1996[73]	Inappropriate population – carotid endarterectomy
Leppala 1999[74]	Inappropriate review focus – long term prognostic risk factors
Lewis 2002[75]	Inappropriate study design – case series

Reference	Reason for exclusion
Li 2018[76]	Inappropriate study design/ No relevant outcomes
Li 2017[77]	Inappropriate study design/No relevant outcomes
Li 2015[78]	Inappropriate population – spontaneous ICH / cerebral infarction
Li 2017[79]	Inappropriate review focus – long term prognostic risk factors
Liang 2018[80]	Inappropriate review focus – predictors of remission
Lindbohm 2016[82]	Inappropriate analysis – Hazard ratios for long-term risk factors of SAH
Lindbohm 2017[81]	Inappropriate analysis – Hazard ratios for long-term risk factors of SAH
Lindbohm 2016[83]	Systematic review – references checked
Lindekleiv 2011[84]	No relevant outcomes – incidence rates
Linn 1998[85]	Inappropriate comparison – comparison of headache symptoms between different conditions
Linn 1994[86]	Inappropriate comparison – all headache patients compared to aSAH
Liotta 2013[87]	Inappropriate study design – No relevant outcomes
Little 2007[88]	Inappropriate study design – case series
Liu 2016[89]	Inappropriate review focus – long term prognostic risk factors
Ljubisavljevic 2017[90]	No relevant outcome – predictors of headache in SAH patients
Lo 2015[91]	Systematic review – references checked
Loumiotis 2011[92]	Inappropriate population – unruptured aneurysms
Lund Haheim 2006[93]	Inappropriate review focus – long term prognostic risk factors
Ma 2019[96]	Inappropriate study design – No relevant outcomes
Ma 2019[95]	Inappropriate population – ICH
Ma 2019[94]	Citation only
Mark 2017[98]	Inappropriate study design/ No relevant outcomes
Menon 2007[99]	Inappropriate study design – descriptive analysis
Mensing 2018[101]	Systematic review – references checked
Mensing 2014[100]	Inappropriate review focus – long term prognostic risk factors
Meretoja 2012[102]	Inappropriate study design/ No relevant outcomes
Migdal 2015[103]	Inappropriate review focus – risk/benefit of LP
Misbach 2001[104]	Inappropriate population – stroke
Mitsos 2008[105]	Inappropriate study design/ No relevant outcomes
Miyagi 2015[106]	Inappropriate comparison – renal function in ICH
Moon 2019[107]	No relevant outcomes – growth of asymptomatic aneurysms
Morgenstern 2001[108]	Inappropriate study design – therapeutic efficacy study
Munoz-Rivas 2016[109]	Inappropriate review focus – diabetes in SAH
Nabaweesi-Batuka 2016[110]	Inappropriate review focus – clinical features of aneurysms
Nahed 2005[111]	Inappropriate review focus – long term prognostic risk factors
Naval 2009[113]	Inappropriate population – spontaneous ICH
Neil-Dwyer 1998[114]	Inappropriate review focus – risk factors for poor outcome
Nemer 1998[115]	Inappropriate population – headache for meningitis, ICH or tumour
Newman 2018[116]	Inappropriate review focus – review of comorbidities in SAH
Nieuwkamp 2009[117]	Systematic review – references checked
Nogueira 1992[118]	Inappropriate population – spontaneous ICH
Nogueira 2018[119]	Inappropriate population – intracranial haemorrhage survivors

Reference	Reason for exclusion
Oder 1991[120]	Inappropriate study design/ No relevant outcomes
Ogun 2002[121]	Inappropriate study design/ No relevant outcomes
Ogun 2001[122]	Inappropriate study design/ No relevant outcomes
Ogunlaja 2019[123]	Inappropriate study design – literature review
Ohkuma 2003[124]	Inappropriate review focus – long term prognostic risk factors
Ohtani 2003[125]	Inappropriate study design/ No relevant outcomes
Ois 2019[126]	Inappropriate review focus – indicators for poor outcome
Olavarria 2014[127]	Inappropriate population – ICH
Oppong 2019[128]	Inappropriate review focus – long term prognostic risk factors
Ozeren 2006[129]	Inappropriate population – ICH
Pavlovic 2018[131]	Inappropriate comparison – comparison of findings between specialists
Perry 2005[134]	No relevant outcome – physician comfort of performing LP
Pierot 2020[135]	Inappropriate population – ruptured and unruptured aneurysms
Pinto 1996[136]	No usable outcomes – comparison of SAH with seizures to without seizures
Plata Bello 2016[137]	Inappropriate comparison – idiopathic SAH compared to aSAH
Polmear 2003[138]	Systematic review – references checked
Powell 2018[139]	Inappropriate review focus – long term prognostic risk factors
Qian 2016[140]	Inappropriate review focus – long term prognostic risk factors
Refai 2008[141]	No usable outcome – chart review and aetiology of SAH patients
Rico 2014[142]	Inappropriate review focus – aetiology of SAH
Rodriguez-Luna 2018[143]	No relevant outcomes
Rosenorn 1994[144]	No relevant outcome – comparison between localization of aneurysm and size
Rush 2016[145]	No relevant outcome – seizure association with mortality in SAH
Sacco 1984[146]	Inappropriate study design/No relevant outcomes
Sahraian 2019[147]	Not review population – not SAH
Sare 2009[148]	Not review population – acute stroke
Savitz 2008[149]	Inappropriate comparison – literature review
Sayer 2015[150]	Inappropriate review focus – diagnosis by LP in CT negative cases
Shimizu 1984[151]	Inappropriate population – cerebral haemorrhage and cerebral infarction
Sim 2016[152]	No usable outcomes – characteristics of patients and aneurysm with SAH
Suthar 2016[153]	Inappropriate review population – ICH
Suwatcharangkoon 2016[154]	Inappropriate study design/ No relevant outcomes
Swope 2014[155]	Inappropriate study design/ No relevant outcomes
Teping 2018[156]	Inappropriate study design/ No relevant outcomes
Toftdahl 1995[157]	No relevant outcome – comparison between hypertension and risk of early death
Tolias 1996[158]	Inappropriate study design/No relevant outcomes
Tsermoulas 2013[159]	Inappropriate study design/ No relevant outcomes
Tsou 2019[160]	Inappropriate comparison – predictors of neurological deterioration
Valenca 2002[161]	Inappropriate study design/ No relevant outcomes
Valle Alonso 2018[162]	Not in English
Vermeulen 2007[163]	No relevant outcomes – missed diagnosis of SAH

Reference	Reason for exclusion
Verweij 1988[164]	Inappropriate study design/ No relevant outcomes
Vlak 2013[165]	Inappropriate population – unruptured aneurysms
Wan 2016[166]	Inappropriate population – ICH
Wang 2017[167]	Inappropriate comparison – relationship between GOS; DCI and LOC
Wei 1994[168]	Not review population – bedside diagnosis of neurological emergencies
Woo 2002[169]	Inappropriate population – ICH
Wu 2016[170]	Inappropriate population – stroke
Ye 2017[171]	Inappropriate study design/ No relevant outcomes
Yeh 2010[172]	Inappropriate population – headache only
Yost 2018[173]	Inappropriate population – spontaneous spinal SAH
Yuksen 2018[174]	Inappropriate population – traumatic brain injury
Zia 2007[175]	Inappropriate study design/ No relevant outcomes
Zidverc-Trajkovic 1998[176]	Inappropriate population - ICH

H.21 Excluded health economic studies

2 Published health economic studies that met the inclusion criteria (relevant population,
3 comparators, economic study design, published 2003 or later and not from non-OECD
4 country or USA) but that were excluded following appraisal of applicability and
5 methodological quality are listed below. See the health economic protocol for more details.

6 **Table 10: Studies excluded from the health economic review**

Reference	Reason for exclusion
None.	

7